{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 440,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "os.chdir('../医疗基因检测报告结果20180814/')\n",
    "import datetime\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 441,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "/Users/andy/Desktop/医疗基因检测报告结果20180814\r\n"
     ]
    }
   ],
   "source": [
    "!pwd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 442,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>化疗药物</th>\n",
       "      <th>基因</th>\n",
       "      <th>位点</th>\n",
       "      <th>基因型</th>\n",
       "      <th>类别</th>\n",
       "      <th>解释</th>\n",
       "      <th>证据等级</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>环磷酰胺+表柔比星</td>\n",
       "      <td>GSTP1</td>\n",
       "      <td>rs1695</td>\n",
       "      <td>AA</td>\n",
       "      <td>疗效较好，毒副较低</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于GG基因型，可能有1）较好的药物效果，2）较低的药物毒性风险。</td>\n",
       "      <td>2A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AG</td>\n",
       "      <td>疗效较好，毒副较低</td>\n",
       "      <td>携带AG基因型的乳腺癌患者，相比于GG基因型，可能有1）较好的药物效果，2）较低的药物毒性风险。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>疗效较差，毒副较高</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于AG和AA基因型，可能有1）较差的药物效果，2）较高的药物...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>环磷酰胺+多柔比星+氟尿嘧啶</td>\n",
       "      <td>ABCC4</td>\n",
       "      <td>rs9561778</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于GT和TT基因型，可能有较低但不消除的的药物不良反应风险。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GT</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带GT基因型的乳腺癌患者，相比于GG基因型，可能有较高的药物不良反应风险。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TT</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带TT基因型的乳腺癌患者，相比于GG基因型，可能有较高的药物不良反应风险。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NaN</td>\n",
       "      <td>ERCC1</td>\n",
       "      <td>rs11615</td>\n",
       "      <td>AA</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于AG和GG基因型，可能有较低的贫血和肾毒性风险。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AG</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较高的贫血和肾毒性风险。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较高的贫血和肾毒性风险。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>多柔比星</td>\n",
       "      <td>CBR3</td>\n",
       "      <td>rs8133052</td>\n",
       "      <td>AA</td>\n",
       "      <td>疗效较好，毒副较高</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于GG基因型，可能有1）较慢的药物代谢，2）较大程度的肿瘤缩...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AG</td>\n",
       "      <td>疗效适中，毒副适中</td>\n",
       "      <td>携带AG基因型的乳腺癌患者，相比于GG基因型，可能有1）较慢的药物代谢，2）较大程度的肿瘤缩...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>携带AG基因型的乳腺癌患者，相比于AA基因型，可能有1）较快的药物代谢，2）较低程度的肿瘤缩...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>疗效较差，毒副较低</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于AA基因型，可能有1）较快的药物代谢，2）较小程度的肿瘤缩...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>环磷酰胺</td>\n",
       "      <td>SOD2</td>\n",
       "      <td>rs4880</td>\n",
       "      <td>AA</td>\n",
       "      <td>疗效较好</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于GG基因型，可能有较长的生存期。</td>\n",
       "      <td>2B</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AG</td>\n",
       "      <td>疗效适中</td>\n",
       "      <td>携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较短的生存期。相比于GG基因型，可能有较...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>疗效较差</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较短的生存期。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>NaN</td>\n",
       "      <td>ABCC4</td>\n",
       "      <td>rs9561778</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于TT基因型，可能有较低但不消除的药物毒副风险，尤其是嗜中性...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GT</td>\n",
       "      <td>毒副适中</td>\n",
       "      <td>携带GT基因型的乳腺癌患者，相比于GG基因型，可能有较高的药物毒副风险，尤其是嗜中性白血球减...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TT</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带TT基因型的乳腺癌患者，相比于GT基因型，可能有较高的药物毒副风险，尤其是嗜中性白血球减...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>紫杉醇</td>\n",
       "      <td>SOD2</td>\n",
       "      <td>rs4880</td>\n",
       "      <td>AA</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于AG或GG基因型，可能有较高的神经病变风险，这种相关性只见...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较低的神经病变风险，这种相关性只见于CY...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较低的神经病变风险，这种相关性只见于CY...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>NaN</td>\n",
       "      <td>ABCB1</td>\n",
       "      <td>rs1045642</td>\n",
       "      <td>AA</td>\n",
       "      <td>疗效较差</td>\n",
       "      <td>携带AA基因型的转移性乳腺癌患者，相比于GG基因型，可能有较低的疾病控制率和较低的总生存率。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>69</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>疗效较好，毒副较低</td>\n",
       "      <td>携带GG基因型的肿瘤患者，相比于AA基因型，可能有（1）较低风险发生嗜中性白血球减少症，（2...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>70</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NT5C2</td>\n",
       "      <td>rs11598702</td>\n",
       "      <td>CC</td>\n",
       "      <td>代谢较快</td>\n",
       "      <td>携带CC基因型的肿瘤患者，相比于TT基因型，可能有较高的药物清除。</td>\n",
       "      <td>2B</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>71</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>72</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CT</td>\n",
       "      <td>代谢较快</td>\n",
       "      <td>携带CT基因型的肿瘤患者，相比于TT基因型，可能有较高的药物清除。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>73</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TT</td>\n",
       "      <td>代谢较慢</td>\n",
       "      <td>携带TT基因型的肿瘤患者，相比于CT和CC基因型，可能有较低的药物清除。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>74</th>\n",
       "      <td>甲氨蝶呤</td>\n",
       "      <td>MTHFR</td>\n",
       "      <td>rs1801133</td>\n",
       "      <td>AA</td>\n",
       "      <td>疗效较差，毒副较高</td>\n",
       "      <td>携带AA基因型的白血病或淋巴瘤患者，相比于AG或GG基因型，可能（1）治疗效果较差，（2）较...</td>\n",
       "      <td>2A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>76</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AG</td>\n",
       "      <td>疗效适中，毒副适中</td>\n",
       "      <td>携带AG基因型的白血病或淋巴瘤患者，相比于GG基因型，可能（1）治疗效果较差，（2）较高的药...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>77</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>携带AG基因型的白血病或淋巴瘤患者，相比于AA基因型，可能（1）治疗效果较好，（2）较低的药...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>78</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>疗效较好，毒副较低</td>\n",
       "      <td>携带GG基因型的白血病或淋巴瘤患者，相比于AA或AG基因型，可能（1）治疗效果较好，（2）有...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>79</th>\n",
       "      <td>他莫昔芬</td>\n",
       "      <td>CYP2D6</td>\n",
       "      <td>rs3892097</td>\n",
       "      <td>CC</td>\n",
       "      <td>疗效较好，毒副较高</td>\n",
       "      <td>携带CC基因型的乳腺癌患者，相比于TT基因型，可能有（1）较低的但不消除的复发风险，（2）较...</td>\n",
       "      <td>2A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>80</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>81</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CT</td>\n",
       "      <td>疗效较好，毒副较高</td>\n",
       "      <td>携带CT基因型的乳腺癌患者，相比于TT基因型，可能有（1）较低的但不消除的复发风险，（2）较...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>82</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TT</td>\n",
       "      <td>疗效较差，毒副较低</td>\n",
       "      <td>携带TT基因型的乳腺癌患者，相比于CT或CC基因型，可能有（1）较高的复发风险，（2）较低发...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>来曲唑、阿那曲唑</td>\n",
       "      <td>TNFSF11</td>\n",
       "      <td>rs7984870</td>\n",
       "      <td>CC</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带CC基因型的乳腺癌患者，相比于CG和GG基因型，可能有较高的芳香酶抑制剂相关的肌肉骨骼综...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带CG基因型的乳腺癌患者，相比于CC基因型，可能有较低的芳香酶抑制剂相关的肌肉骨骼综合征，...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于CC基因型，可能有较低的芳香酶抑制剂相关的肌肉骨骼综合征，...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>NaN</td>\n",
       "      <td>CYP19A1</td>\n",
       "      <td>rs4646</td>\n",
       "      <td>AA</td>\n",
       "      <td>绝经前疗效较好，绝经后疗效较差</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于AC和CC基因型，对于绝经前的女性，可能有较好的治疗效果。...</td>\n",
       "      <td>2B</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>89</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AC</td>\n",
       "      <td>绝经前疗效较差，绝经后疗效较好</td>\n",
       "      <td>携带AC基因型的乳腺癌患者，相比于AA基因型，对于绝经前的女性，可能有较差的治疗效果。对于绝...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>90</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CC</td>\n",
       "      <td>绝经前疗效较差，绝经后疗效较好</td>\n",
       "      <td>携带CC基因型的乳腺癌患者，相比于AA基因型，对于绝经前的女性，可能有较差的治疗效果。对于绝...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>91</th>\n",
       "      <td>依西美坦</td>\n",
       "      <td>CYP19A1</td>\n",
       "      <td>rs7176005</td>\n",
       "      <td>CC</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带CC基因型的绝经后激素受体（HR）阳性乳腺癌患者，相比于TT基因型，可能有较低的血管舒缩...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>92</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>93</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CT</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带CT基因型的绝经后激素受体（HR）阳性乳腺癌患者，相比于TT基因型，可能有较低的血管舒缩...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>94</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TT</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带TT基因型的绝经后激素受体（HR）阳性乳腺癌患者，相比于CC或CT基因型，可能有较高的血...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>NaN</td>\n",
       "      <td>ESR1</td>\n",
       "      <td>rs2813543</td>\n",
       "      <td>AA</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于AG和GG基因型，可能有较低的骨密度流失风险。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>96</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AG</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较高的骨密度流失风险。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>98</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较高的骨密度流失风险。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>99 rows × 7 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "              化疗药物       基因          位点  基因型               类别  \\\n",
       "0        环磷酰胺+表柔比星    GSTP1      rs1695   AA        疗效较好，毒副较低   \n",
       "1              NaN      NaN         NaN   AG        疗效较好，毒副较低   \n",
       "2              NaN      NaN         NaN   GG        疗效较差，毒副较高   \n",
       "3   环磷酰胺+多柔比星+氟尿嘧啶    ABCC4   rs9561778   GG             毒副较低   \n",
       "4              NaN      NaN         NaN  NaN              NaN   \n",
       "5              NaN      NaN         NaN   GT             毒副较高   \n",
       "6              NaN      NaN         NaN   TT             毒副较高   \n",
       "7              NaN    ERCC1     rs11615   AA             毒副较低   \n",
       "8              NaN      NaN         NaN  NaN              NaN   \n",
       "9              NaN      NaN         NaN   AG             毒副较高   \n",
       "10             NaN      NaN         NaN   GG             毒副较高   \n",
       "11            多柔比星     CBR3   rs8133052   AA        疗效较好，毒副较高   \n",
       "12             NaN      NaN         NaN  NaN              NaN   \n",
       "13             NaN      NaN         NaN   AG        疗效适中，毒副适中   \n",
       "14             NaN      NaN         NaN  NaN              NaN   \n",
       "15             NaN      NaN         NaN  NaN              NaN   \n",
       "16             NaN      NaN         NaN   GG        疗效较差，毒副较低   \n",
       "17            环磷酰胺     SOD2      rs4880   AA             疗效较好   \n",
       "18             NaN      NaN         NaN  NaN              NaN   \n",
       "19             NaN      NaN         NaN   AG             疗效适中   \n",
       "20             NaN      NaN         NaN   GG             疗效较差   \n",
       "21             NaN    ABCC4   rs9561778   GG             毒副较低   \n",
       "22             NaN      NaN         NaN  NaN              NaN   \n",
       "23             NaN      NaN         NaN   GT             毒副适中   \n",
       "24             NaN      NaN         NaN   TT             毒副较高   \n",
       "25             紫杉醇     SOD2      rs4880   AA             毒副较高   \n",
       "26             NaN      NaN         NaN  NaN              NaN   \n",
       "27             NaN      NaN         NaN   AG             毒副较低   \n",
       "28             NaN      NaN         NaN   GG             毒副较低   \n",
       "29             NaN    ABCB1   rs1045642   AA             疗效较差   \n",
       "..             ...      ...         ...  ...              ...   \n",
       "69             NaN      NaN         NaN   GG        疗效较好，毒副较低   \n",
       "70             NaN    NT5C2  rs11598702   CC             代谢较快   \n",
       "71             NaN      NaN         NaN  NaN              NaN   \n",
       "72             NaN      NaN         NaN   CT             代谢较快   \n",
       "73             NaN      NaN         NaN   TT             代谢较慢   \n",
       "74            甲氨蝶呤    MTHFR   rs1801133   AA        疗效较差，毒副较高   \n",
       "75             NaN      NaN         NaN  NaN              NaN   \n",
       "76             NaN      NaN         NaN   AG        疗效适中，毒副适中   \n",
       "77             NaN      NaN         NaN  NaN              NaN   \n",
       "78             NaN      NaN         NaN   GG        疗效较好，毒副较低   \n",
       "79            他莫昔芬   CYP2D6   rs3892097   CC        疗效较好，毒副较高   \n",
       "80             NaN      NaN         NaN  NaN              NaN   \n",
       "81             NaN      NaN         NaN   CT        疗效较好，毒副较高   \n",
       "82             NaN      NaN         NaN   TT        疗效较差，毒副较低   \n",
       "83        来曲唑、阿那曲唑  TNFSF11   rs7984870   CC             毒副较高   \n",
       "84             NaN      NaN         NaN  NaN              NaN   \n",
       "85             NaN      NaN         NaN   CG             毒副较低   \n",
       "86             NaN      NaN         NaN   GG             毒副较低   \n",
       "87             NaN  CYP19A1      rs4646   AA  绝经前疗效较好，绝经后疗效较差   \n",
       "88             NaN      NaN         NaN  NaN              NaN   \n",
       "89             NaN      NaN         NaN   AC  绝经前疗效较差，绝经后疗效较好   \n",
       "90             NaN      NaN         NaN   CC  绝经前疗效较差，绝经后疗效较好   \n",
       "91            依西美坦  CYP19A1   rs7176005   CC             毒副较低   \n",
       "92             NaN      NaN         NaN  NaN              NaN   \n",
       "93             NaN      NaN         NaN   CT             毒副较低   \n",
       "94             NaN      NaN         NaN   TT             毒副较高   \n",
       "95             NaN     ESR1   rs2813543   AA             毒副较低   \n",
       "96             NaN      NaN         NaN  NaN              NaN   \n",
       "97             NaN      NaN         NaN   AG             毒副较高   \n",
       "98             NaN      NaN         NaN   GG             毒副较高   \n",
       "\n",
       "                                                   解释 证据等级  \n",
       "0    携带AA基因型的乳腺癌患者，相比于GG基因型，可能有1）较好的药物效果，2）较低的药物毒性风险。   2A  \n",
       "1    携带AG基因型的乳腺癌患者，相比于GG基因型，可能有1）较好的药物效果，2）较低的药物毒性风险。  NaN  \n",
       "2   携带GG基因型的乳腺癌患者，相比于AG和AA基因型，可能有1）较差的药物效果，2）较高的药物...  NaN  \n",
       "3      携带GG基因型的乳腺癌患者，相比于GT和TT基因型，可能有较低但不消除的的药物不良反应风险。    3  \n",
       "4                                                 NaN  NaN  \n",
       "5              携带GT基因型的乳腺癌患者，相比于GG基因型，可能有较高的药物不良反应风险。  NaN  \n",
       "6              携带TT基因型的乳腺癌患者，相比于GG基因型，可能有较高的药物不良反应风险。  NaN  \n",
       "7           携带AA基因型的乳腺癌患者，相比于AG和GG基因型，可能有较低的贫血和肾毒性风险。    3  \n",
       "8                                                 NaN  NaN  \n",
       "9              携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较高的贫血和肾毒性风险。  NaN  \n",
       "10             携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较高的贫血和肾毒性风险。  NaN  \n",
       "11  携带AA基因型的乳腺癌患者，相比于GG基因型，可能有1）较慢的药物代谢，2）较大程度的肿瘤缩...    3  \n",
       "12                                                NaN  NaN  \n",
       "13  携带AG基因型的乳腺癌患者，相比于GG基因型，可能有1）较慢的药物代谢，2）较大程度的肿瘤缩...  NaN  \n",
       "14  携带AG基因型的乳腺癌患者，相比于AA基因型，可能有1）较快的药物代谢，2）较低程度的肿瘤缩...  NaN  \n",
       "15                                                NaN  NaN  \n",
       "16  携带GG基因型的乳腺癌患者，相比于AA基因型，可能有1）较快的药物代谢，2）较小程度的肿瘤缩...  NaN  \n",
       "17                  携带AA基因型的乳腺癌患者，相比于GG基因型，可能有较长的生存期。   2B  \n",
       "18                                                NaN  NaN  \n",
       "19  携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较短的生存期。相比于GG基因型，可能有较...  NaN  \n",
       "20                  携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较短的生存期。  NaN  \n",
       "21  携带GG基因型的乳腺癌患者，相比于TT基因型，可能有较低但不消除的药物毒副风险，尤其是嗜中性...    3  \n",
       "22                                                NaN  NaN  \n",
       "23  携带GT基因型的乳腺癌患者，相比于GG基因型，可能有较高的药物毒副风险，尤其是嗜中性白血球减...  NaN  \n",
       "24  携带TT基因型的乳腺癌患者，相比于GT基因型，可能有较高的药物毒副风险，尤其是嗜中性白血球减...  NaN  \n",
       "25  携带AA基因型的乳腺癌患者，相比于AG或GG基因型，可能有较高的神经病变风险，这种相关性只见...    3  \n",
       "26                                                NaN  NaN  \n",
       "27  携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较低的神经病变风险，这种相关性只见于CY...  NaN  \n",
       "28  携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较低的神经病变风险，这种相关性只见于CY...  NaN  \n",
       "29     携带AA基因型的转移性乳腺癌患者，相比于GG基因型，可能有较低的疾病控制率和较低的总生存率。    3  \n",
       "..                                                ...  ...  \n",
       "69  携带GG基因型的肿瘤患者，相比于AA基因型，可能有（1）较低风险发生嗜中性白血球减少症，（2...  NaN  \n",
       "70                  携带CC基因型的肿瘤患者，相比于TT基因型，可能有较高的药物清除。   2B  \n",
       "71                                                NaN  NaN  \n",
       "72                  携带CT基因型的肿瘤患者，相比于TT基因型，可能有较高的药物清除。  NaN  \n",
       "73               携带TT基因型的肿瘤患者，相比于CT和CC基因型，可能有较低的药物清除。  NaN  \n",
       "74  携带AA基因型的白血病或淋巴瘤患者，相比于AG或GG基因型，可能（1）治疗效果较差，（2）较...   2A  \n",
       "75                                                NaN  NaN  \n",
       "76  携带AG基因型的白血病或淋巴瘤患者，相比于GG基因型，可能（1）治疗效果较差，（2）较高的药...  NaN  \n",
       "77  携带AG基因型的白血病或淋巴瘤患者，相比于AA基因型，可能（1）治疗效果较好，（2）较低的药...  NaN  \n",
       "78  携带GG基因型的白血病或淋巴瘤患者，相比于AA或AG基因型，可能（1）治疗效果较好，（2）有...  NaN  \n",
       "79  携带CC基因型的乳腺癌患者，相比于TT基因型，可能有（1）较低的但不消除的复发风险，（2）较...   2A  \n",
       "80                                                NaN  NaN  \n",
       "81  携带CT基因型的乳腺癌患者，相比于TT基因型，可能有（1）较低的但不消除的复发风险，（2）较...  NaN  \n",
       "82  携带TT基因型的乳腺癌患者，相比于CT或CC基因型，可能有（1）较高的复发风险，（2）较低发...  NaN  \n",
       "83  携带CC基因型的乳腺癌患者，相比于CG和GG基因型，可能有较高的芳香酶抑制剂相关的肌肉骨骼综...    3  \n",
       "84                                                NaN  NaN  \n",
       "85  携带CG基因型的乳腺癌患者，相比于CC基因型，可能有较低的芳香酶抑制剂相关的肌肉骨骼综合征，...  NaN  \n",
       "86  携带GG基因型的乳腺癌患者，相比于CC基因型，可能有较低的芳香酶抑制剂相关的肌肉骨骼综合征，...  NaN  \n",
       "87  携带AA基因型的乳腺癌患者，相比于AC和CC基因型，对于绝经前的女性，可能有较好的治疗效果。...   2B  \n",
       "88                                                NaN  NaN  \n",
       "89  携带AC基因型的乳腺癌患者，相比于AA基因型，对于绝经前的女性，可能有较差的治疗效果。对于绝...  NaN  \n",
       "90  携带CC基因型的乳腺癌患者，相比于AA基因型，对于绝经前的女性，可能有较差的治疗效果。对于绝...  NaN  \n",
       "91  携带CC基因型的绝经后激素受体（HR）阳性乳腺癌患者，相比于TT基因型，可能有较低的血管舒缩...    3  \n",
       "92                                                NaN  NaN  \n",
       "93  携带CT基因型的绝经后激素受体（HR）阳性乳腺癌患者，相比于TT基因型，可能有较低的血管舒缩...  NaN  \n",
       "94  携带TT基因型的绝经后激素受体（HR）阳性乳腺癌患者，相比于CC或CT基因型，可能有较高的血...  NaN  \n",
       "95           携带AA基因型的乳腺癌患者，相比于AG和GG基因型，可能有较低的骨密度流失风险。    3  \n",
       "96                                                NaN  NaN  \n",
       "97              携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较高的骨密度流失风险。  NaN  \n",
       "98              携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较高的骨密度流失风险。  NaN  \n",
       "\n",
       "[99 rows x 7 columns]"
      ]
     },
     "execution_count": 442,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import re\n",
    "import pandas as pd\n",
    "df = pd.read_excel('新乳腺癌化疗用药数据库.xlsx')\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 443,
   "metadata": {},
   "outputs": [],
   "source": [
    "df = df.dropna(axis = 0, subset = ['类别'] )\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 444,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>化疗药物</th>\n",
       "      <th>基因</th>\n",
       "      <th>位点</th>\n",
       "      <th>基因型</th>\n",
       "      <th>类别</th>\n",
       "      <th>解释</th>\n",
       "      <th>证据等级</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>环磷酰胺+表柔比星</td>\n",
       "      <td>GSTP1</td>\n",
       "      <td>rs1695</td>\n",
       "      <td>AA</td>\n",
       "      <td>疗效较好，毒副较低</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于GG基因型，可能有1）较好的药物效果，2）较低的药物毒性风险。</td>\n",
       "      <td>2A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AG</td>\n",
       "      <td>疗效较好，毒副较低</td>\n",
       "      <td>携带AG基因型的乳腺癌患者，相比于GG基因型，可能有1）较好的药物效果，2）较低的药物毒性风险。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>疗效较差，毒副较高</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于AG和AA基因型，可能有1）较差的药物效果，2）较高的药物...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>环磷酰胺+多柔比星+氟尿嘧啶</td>\n",
       "      <td>ABCC4</td>\n",
       "      <td>rs9561778</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于GT和TT基因型，可能有较低但不消除的的药物不良反应风险。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GT</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带GT基因型的乳腺癌患者，相比于GG基因型，可能有较高的药物不良反应风险。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TT</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带TT基因型的乳腺癌患者，相比于GG基因型，可能有较高的药物不良反应风险。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NaN</td>\n",
       "      <td>ERCC1</td>\n",
       "      <td>rs11615</td>\n",
       "      <td>AA</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于AG和GG基因型，可能有较低的贫血和肾毒性风险。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AG</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较高的贫血和肾毒性风险。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较高的贫血和肾毒性风险。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>多柔比星</td>\n",
       "      <td>CBR3</td>\n",
       "      <td>rs8133052</td>\n",
       "      <td>AA</td>\n",
       "      <td>疗效较好，毒副较高</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于GG基因型，可能有1）较慢的药物代谢，2）较大程度的肿瘤缩...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AG</td>\n",
       "      <td>疗效适中，毒副适中</td>\n",
       "      <td>携带AG基因型的乳腺癌患者，相比于GG基因型，可能有1）较慢的药物代谢，2）较大程度的肿瘤缩...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>疗效较差，毒副较低</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于AA基因型，可能有1）较快的药物代谢，2）较小程度的肿瘤缩...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>环磷酰胺</td>\n",
       "      <td>SOD2</td>\n",
       "      <td>rs4880</td>\n",
       "      <td>AA</td>\n",
       "      <td>疗效较好</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于GG基因型，可能有较长的生存期。</td>\n",
       "      <td>2B</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AG</td>\n",
       "      <td>疗效适中</td>\n",
       "      <td>携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较短的生存期。相比于GG基因型，可能有较...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>疗效较差</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较短的生存期。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>NaN</td>\n",
       "      <td>ABCC4</td>\n",
       "      <td>rs9561778</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于TT基因型，可能有较低但不消除的药物毒副风险，尤其是嗜中性...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GT</td>\n",
       "      <td>毒副适中</td>\n",
       "      <td>携带GT基因型的乳腺癌患者，相比于GG基因型，可能有较高的药物毒副风险，尤其是嗜中性白血球减...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TT</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带TT基因型的乳腺癌患者，相比于GT基因型，可能有较高的药物毒副风险，尤其是嗜中性白血球减...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>紫杉醇</td>\n",
       "      <td>SOD2</td>\n",
       "      <td>rs4880</td>\n",
       "      <td>AA</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于AG或GG基因型，可能有较高的神经病变风险，这种相关性只见...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较低的神经病变风险，这种相关性只见于CY...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较低的神经病变风险，这种相关性只见于CY...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>NaN</td>\n",
       "      <td>ABCB1</td>\n",
       "      <td>rs1045642</td>\n",
       "      <td>AA</td>\n",
       "      <td>疗效较差</td>\n",
       "      <td>携带AA基因型的转移性乳腺癌患者，相比于GG基因型，可能有较低的疾病控制率和较低的总生存率。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AG</td>\n",
       "      <td>疗效较差</td>\n",
       "      <td>携带AG基因型的转移性乳腺癌患者，相比于GG基因型，可能有较低的疾病控制率和较低的总生存率。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>疗效较好</td>\n",
       "      <td>携带GG基因型的转移性乳腺癌患者，相比于AG基因型，可能有较高的疾病控制率和较高的总生存率。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>多西他赛</td>\n",
       "      <td>ERCC2</td>\n",
       "      <td>rs13181</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于TT基因型，可能有较低的嗜中性白血球减少症的风险，但在肌病...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GT</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带GT基因型的乳腺癌患者，相比于TT基因型，可能有较低的嗜中性白血球减少症的风险，但在肌病...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TT</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带TT基因型的乳腺癌患者，相比于GG或GT基因型，可能有较高的嗜中性白血球减少症的风险，但...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>NaN</td>\n",
       "      <td>VEGFA</td>\n",
       "      <td>rs699947</td>\n",
       "      <td>AA</td>\n",
       "      <td>疗效较好</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于CC基因型，可能有较长的无进展生存期。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AC</td>\n",
       "      <td>疗效适中</td>\n",
       "      <td>未有研究发现</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CC</td>\n",
       "      <td>疗效较差</td>\n",
       "      <td>携带CC基因型的乳腺癌患者，相比于AA基因型，可能有较短的无进展生存期。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>NaN</td>\n",
       "      <td>TYMS</td>\n",
       "      <td>rs151264360</td>\n",
       "      <td>TTAAAG/TTAAAG</td>\n",
       "      <td>疗效较差，毒副较低</td>\n",
       "      <td>携带TTAAAG/TTAAAG基因型的肿瘤患者，相比于TTAAAG/del 或del/del...</td>\n",
       "      <td>2A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>60</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TTAAAG/del</td>\n",
       "      <td>疗效适中，毒副适中</td>\n",
       "      <td>携带TTAAAG/del基因型的肿瘤患者，相比于TTAAAG/TTAAAG基因型，可能有较长...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>61</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>(-/-)</td>\n",
       "      <td>疗效较好，毒副较高</td>\n",
       "      <td>携带del/del基因型的肿瘤患者，相比于TTAAAG/TTAAAG或TTAAAG/del基...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>62</th>\n",
       "      <td>吉西他滨</td>\n",
       "      <td>RRM1</td>\n",
       "      <td>rs1042858</td>\n",
       "      <td>AA</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带AA基因型且在rs9937位点携带G等位基因的乳腺癌患者，相比于GG基因型，可能会降低毒...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>64</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带AG基因型且在rs9937位点携带G等位基因的乳腺癌患者，相比于GG基因型，可能会降低毒...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>65</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带GG基因型且在rs9937位点携带G等位基因的乳腺癌患者，相比于AA或AG基因型，可能会...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>66</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>rs9937</td>\n",
       "      <td>AA</td>\n",
       "      <td>疗效较差，毒副较高</td>\n",
       "      <td>携带AA基因型的肿瘤患者，相比于AG或GG基因型，可能有（1）较高风险发生嗜中性白血球减少症...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>68</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AG</td>\n",
       "      <td>疗效较好，毒副较低</td>\n",
       "      <td>携带AG基因型的肿瘤患者，相比于AA基因型，可能有（1）较低风险发生嗜中性白血球减少症，（2...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>69</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>疗效较好，毒副较低</td>\n",
       "      <td>携带GG基因型的肿瘤患者，相比于AA基因型，可能有（1）较低风险发生嗜中性白血球减少症，（2...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>70</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NT5C2</td>\n",
       "      <td>rs11598702</td>\n",
       "      <td>CC</td>\n",
       "      <td>代谢较快</td>\n",
       "      <td>携带CC基因型的肿瘤患者，相比于TT基因型，可能有较高的药物清除。</td>\n",
       "      <td>2B</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>72</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CT</td>\n",
       "      <td>代谢较快</td>\n",
       "      <td>携带CT基因型的肿瘤患者，相比于TT基因型，可能有较高的药物清除。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>73</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TT</td>\n",
       "      <td>代谢较慢</td>\n",
       "      <td>携带TT基因型的肿瘤患者，相比于CT和CC基因型，可能有较低的药物清除。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>74</th>\n",
       "      <td>甲氨蝶呤</td>\n",
       "      <td>MTHFR</td>\n",
       "      <td>rs1801133</td>\n",
       "      <td>AA</td>\n",
       "      <td>疗效较差，毒副较高</td>\n",
       "      <td>携带AA基因型的白血病或淋巴瘤患者，相比于AG或GG基因型，可能（1）治疗效果较差，（2）较...</td>\n",
       "      <td>2A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>76</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AG</td>\n",
       "      <td>疗效适中，毒副适中</td>\n",
       "      <td>携带AG基因型的白血病或淋巴瘤患者，相比于GG基因型，可能（1）治疗效果较差，（2）较高的药...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>78</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>疗效较好，毒副较低</td>\n",
       "      <td>携带GG基因型的白血病或淋巴瘤患者，相比于AA或AG基因型，可能（1）治疗效果较好，（2）有...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>79</th>\n",
       "      <td>他莫昔芬</td>\n",
       "      <td>CYP2D6</td>\n",
       "      <td>rs3892097</td>\n",
       "      <td>CC</td>\n",
       "      <td>疗效较好，毒副较高</td>\n",
       "      <td>携带CC基因型的乳腺癌患者，相比于TT基因型，可能有（1）较低的但不消除的复发风险，（2）较...</td>\n",
       "      <td>2A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>81</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CT</td>\n",
       "      <td>疗效较好，毒副较高</td>\n",
       "      <td>携带CT基因型的乳腺癌患者，相比于TT基因型，可能有（1）较低的但不消除的复发风险，（2）较...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>82</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TT</td>\n",
       "      <td>疗效较差，毒副较低</td>\n",
       "      <td>携带TT基因型的乳腺癌患者，相比于CT或CC基因型，可能有（1）较高的复发风险，（2）较低发...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>来曲唑、阿那曲唑</td>\n",
       "      <td>TNFSF11</td>\n",
       "      <td>rs7984870</td>\n",
       "      <td>CC</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带CC基因型的乳腺癌患者，相比于CG和GG基因型，可能有较高的芳香酶抑制剂相关的肌肉骨骼综...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带CG基因型的乳腺癌患者，相比于CC基因型，可能有较低的芳香酶抑制剂相关的肌肉骨骼综合征，...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于CC基因型，可能有较低的芳香酶抑制剂相关的肌肉骨骼综合征，...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>NaN</td>\n",
       "      <td>CYP19A1</td>\n",
       "      <td>rs4646</td>\n",
       "      <td>AA</td>\n",
       "      <td>绝经前疗效较好，绝经后疗效较差</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于AC和CC基因型，对于绝经前的女性，可能有较好的治疗效果。...</td>\n",
       "      <td>2B</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>89</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AC</td>\n",
       "      <td>绝经前疗效较差，绝经后疗效较好</td>\n",
       "      <td>携带AC基因型的乳腺癌患者，相比于AA基因型，对于绝经前的女性，可能有较差的治疗效果。对于绝...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>90</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CC</td>\n",
       "      <td>绝经前疗效较差，绝经后疗效较好</td>\n",
       "      <td>携带CC基因型的乳腺癌患者，相比于AA基因型，对于绝经前的女性，可能有较差的治疗效果。对于绝...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>91</th>\n",
       "      <td>依西美坦</td>\n",
       "      <td>CYP19A1</td>\n",
       "      <td>rs7176005</td>\n",
       "      <td>CC</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带CC基因型的绝经后激素受体（HR）阳性乳腺癌患者，相比于TT基因型，可能有较低的血管舒缩...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>93</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CT</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带CT基因型的绝经后激素受体（HR）阳性乳腺癌患者，相比于TT基因型，可能有较低的血管舒缩...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>94</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TT</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带TT基因型的绝经后激素受体（HR）阳性乳腺癌患者，相比于CC或CT基因型，可能有较高的血...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>NaN</td>\n",
       "      <td>ESR1</td>\n",
       "      <td>rs2813543</td>\n",
       "      <td>AA</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于AG和GG基因型，可能有较低的骨密度流失风险。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AG</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较高的骨密度流失风险。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>98</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较高的骨密度流失风险。</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>72 rows × 7 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "              化疗药物       基因           位点            基因型               类别  \\\n",
       "0        环磷酰胺+表柔比星    GSTP1       rs1695             AA        疗效较好，毒副较低   \n",
       "1              NaN      NaN          NaN             AG        疗效较好，毒副较低   \n",
       "2              NaN      NaN          NaN             GG        疗效较差，毒副较高   \n",
       "3   环磷酰胺+多柔比星+氟尿嘧啶    ABCC4    rs9561778             GG             毒副较低   \n",
       "5              NaN      NaN          NaN             GT             毒副较高   \n",
       "6              NaN      NaN          NaN             TT             毒副较高   \n",
       "7              NaN    ERCC1      rs11615             AA             毒副较低   \n",
       "9              NaN      NaN          NaN             AG             毒副较高   \n",
       "10             NaN      NaN          NaN             GG             毒副较高   \n",
       "11            多柔比星     CBR3    rs8133052             AA        疗效较好，毒副较高   \n",
       "13             NaN      NaN          NaN             AG        疗效适中，毒副适中   \n",
       "16             NaN      NaN          NaN             GG        疗效较差，毒副较低   \n",
       "17            环磷酰胺     SOD2       rs4880             AA             疗效较好   \n",
       "19             NaN      NaN          NaN             AG             疗效适中   \n",
       "20             NaN      NaN          NaN             GG             疗效较差   \n",
       "21             NaN    ABCC4    rs9561778             GG             毒副较低   \n",
       "23             NaN      NaN          NaN             GT             毒副适中   \n",
       "24             NaN      NaN          NaN             TT             毒副较高   \n",
       "25             紫杉醇     SOD2       rs4880             AA             毒副较高   \n",
       "27             NaN      NaN          NaN             AG             毒副较低   \n",
       "28             NaN      NaN          NaN             GG             毒副较低   \n",
       "29             NaN    ABCB1    rs1045642             AA             疗效较差   \n",
       "31             NaN      NaN          NaN             AG             疗效较差   \n",
       "32             NaN      NaN          NaN             GG             疗效较好   \n",
       "33            多西他赛    ERCC2      rs13181             GG             毒副较低   \n",
       "35             NaN      NaN          NaN             GT             毒副较低   \n",
       "36             NaN      NaN          NaN             TT             毒副较高   \n",
       "37             NaN    VEGFA     rs699947             AA             疗效较好   \n",
       "39             NaN      NaN          NaN             AC             疗效适中   \n",
       "40             NaN      NaN          NaN             CC             疗效较差   \n",
       "..             ...      ...          ...            ...              ...   \n",
       "58             NaN     TYMS  rs151264360  TTAAAG/TTAAAG        疗效较差，毒副较低   \n",
       "60             NaN      NaN          NaN     TTAAAG/del        疗效适中，毒副适中   \n",
       "61             NaN      NaN          NaN          (-/-)        疗效较好，毒副较高   \n",
       "62            吉西他滨     RRM1    rs1042858             AA             毒副较低   \n",
       "64             NaN      NaN          NaN             AG             毒副较低   \n",
       "65             NaN      NaN          NaN             GG             毒副较高   \n",
       "66             NaN      NaN       rs9937             AA        疗效较差，毒副较高   \n",
       "68             NaN      NaN          NaN             AG        疗效较好，毒副较低   \n",
       "69             NaN      NaN          NaN             GG        疗效较好，毒副较低   \n",
       "70             NaN    NT5C2   rs11598702             CC             代谢较快   \n",
       "72             NaN      NaN          NaN             CT             代谢较快   \n",
       "73             NaN      NaN          NaN             TT             代谢较慢   \n",
       "74            甲氨蝶呤    MTHFR    rs1801133             AA        疗效较差，毒副较高   \n",
       "76             NaN      NaN          NaN             AG        疗效适中，毒副适中   \n",
       "78             NaN      NaN          NaN             GG        疗效较好，毒副较低   \n",
       "79            他莫昔芬   CYP2D6    rs3892097             CC        疗效较好，毒副较高   \n",
       "81             NaN      NaN          NaN             CT        疗效较好，毒副较高   \n",
       "82             NaN      NaN          NaN             TT        疗效较差，毒副较低   \n",
       "83        来曲唑、阿那曲唑  TNFSF11    rs7984870             CC             毒副较高   \n",
       "85             NaN      NaN          NaN             CG             毒副较低   \n",
       "86             NaN      NaN          NaN             GG             毒副较低   \n",
       "87             NaN  CYP19A1       rs4646             AA  绝经前疗效较好，绝经后疗效较差   \n",
       "89             NaN      NaN          NaN             AC  绝经前疗效较差，绝经后疗效较好   \n",
       "90             NaN      NaN          NaN             CC  绝经前疗效较差，绝经后疗效较好   \n",
       "91            依西美坦  CYP19A1    rs7176005             CC             毒副较低   \n",
       "93             NaN      NaN          NaN             CT             毒副较低   \n",
       "94             NaN      NaN          NaN             TT             毒副较高   \n",
       "95             NaN     ESR1    rs2813543             AA             毒副较低   \n",
       "97             NaN      NaN          NaN             AG             毒副较高   \n",
       "98             NaN      NaN          NaN             GG             毒副较高   \n",
       "\n",
       "                                                   解释 证据等级  \n",
       "0    携带AA基因型的乳腺癌患者，相比于GG基因型，可能有1）较好的药物效果，2）较低的药物毒性风险。   2A  \n",
       "1    携带AG基因型的乳腺癌患者，相比于GG基因型，可能有1）较好的药物效果，2）较低的药物毒性风险。  NaN  \n",
       "2   携带GG基因型的乳腺癌患者，相比于AG和AA基因型，可能有1）较差的药物效果，2）较高的药物...  NaN  \n",
       "3      携带GG基因型的乳腺癌患者，相比于GT和TT基因型，可能有较低但不消除的的药物不良反应风险。    3  \n",
       "5              携带GT基因型的乳腺癌患者，相比于GG基因型，可能有较高的药物不良反应风险。  NaN  \n",
       "6              携带TT基因型的乳腺癌患者，相比于GG基因型，可能有较高的药物不良反应风险。  NaN  \n",
       "7           携带AA基因型的乳腺癌患者，相比于AG和GG基因型，可能有较低的贫血和肾毒性风险。    3  \n",
       "9              携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较高的贫血和肾毒性风险。  NaN  \n",
       "10             携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较高的贫血和肾毒性风险。  NaN  \n",
       "11  携带AA基因型的乳腺癌患者，相比于GG基因型，可能有1）较慢的药物代谢，2）较大程度的肿瘤缩...    3  \n",
       "13  携带AG基因型的乳腺癌患者，相比于GG基因型，可能有1）较慢的药物代谢，2）较大程度的肿瘤缩...  NaN  \n",
       "16  携带GG基因型的乳腺癌患者，相比于AA基因型，可能有1）较快的药物代谢，2）较小程度的肿瘤缩...  NaN  \n",
       "17                  携带AA基因型的乳腺癌患者，相比于GG基因型，可能有较长的生存期。   2B  \n",
       "19  携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较短的生存期。相比于GG基因型，可能有较...  NaN  \n",
       "20                  携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较短的生存期。  NaN  \n",
       "21  携带GG基因型的乳腺癌患者，相比于TT基因型，可能有较低但不消除的药物毒副风险，尤其是嗜中性...    3  \n",
       "23  携带GT基因型的乳腺癌患者，相比于GG基因型，可能有较高的药物毒副风险，尤其是嗜中性白血球减...  NaN  \n",
       "24  携带TT基因型的乳腺癌患者，相比于GT基因型，可能有较高的药物毒副风险，尤其是嗜中性白血球减...  NaN  \n",
       "25  携带AA基因型的乳腺癌患者，相比于AG或GG基因型，可能有较高的神经病变风险，这种相关性只见...    3  \n",
       "27  携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较低的神经病变风险，这种相关性只见于CY...  NaN  \n",
       "28  携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较低的神经病变风险，这种相关性只见于CY...  NaN  \n",
       "29     携带AA基因型的转移性乳腺癌患者，相比于GG基因型，可能有较低的疾病控制率和较低的总生存率。    3  \n",
       "31     携带AG基因型的转移性乳腺癌患者，相比于GG基因型，可能有较低的疾病控制率和较低的总生存率。  NaN  \n",
       "32     携带GG基因型的转移性乳腺癌患者，相比于AG基因型，可能有较高的疾病控制率和较高的总生存率。  NaN  \n",
       "33  携带GG基因型的乳腺癌患者，相比于TT基因型，可能有较低的嗜中性白血球减少症的风险，但在肌病...    3  \n",
       "35  携带GT基因型的乳腺癌患者，相比于TT基因型，可能有较低的嗜中性白血球减少症的风险，但在肌病...  NaN  \n",
       "36  携带TT基因型的乳腺癌患者，相比于GG或GT基因型，可能有较高的嗜中性白血球减少症的风险，但...  NaN  \n",
       "37               携带AA基因型的乳腺癌患者，相比于CC基因型，可能有较长的无进展生存期。    3  \n",
       "39                                             未有研究发现  NaN  \n",
       "40               携带CC基因型的乳腺癌患者，相比于AA基因型，可能有较短的无进展生存期。  NaN  \n",
       "..                                                ...  ...  \n",
       "58  携带TTAAAG/TTAAAG基因型的肿瘤患者，相比于TTAAAG/del 或del/del...   2A  \n",
       "60  携带TTAAAG/del基因型的肿瘤患者，相比于TTAAAG/TTAAAG基因型，可能有较长...  NaN  \n",
       "61  携带del/del基因型的肿瘤患者，相比于TTAAAG/TTAAAG或TTAAAG/del基...  NaN  \n",
       "62  携带AA基因型且在rs9937位点携带G等位基因的乳腺癌患者，相比于GG基因型，可能会降低毒...    3  \n",
       "64  携带AG基因型且在rs9937位点携带G等位基因的乳腺癌患者，相比于GG基因型，可能会降低毒...  NaN  \n",
       "65  携带GG基因型且在rs9937位点携带G等位基因的乳腺癌患者，相比于AA或AG基因型，可能会...  NaN  \n",
       "66  携带AA基因型的肿瘤患者，相比于AG或GG基因型，可能有（1）较高风险发生嗜中性白血球减少症...    3  \n",
       "68  携带AG基因型的肿瘤患者，相比于AA基因型，可能有（1）较低风险发生嗜中性白血球减少症，（2...  NaN  \n",
       "69  携带GG基因型的肿瘤患者，相比于AA基因型，可能有（1）较低风险发生嗜中性白血球减少症，（2...  NaN  \n",
       "70                  携带CC基因型的肿瘤患者，相比于TT基因型，可能有较高的药物清除。   2B  \n",
       "72                  携带CT基因型的肿瘤患者，相比于TT基因型，可能有较高的药物清除。  NaN  \n",
       "73               携带TT基因型的肿瘤患者，相比于CT和CC基因型，可能有较低的药物清除。  NaN  \n",
       "74  携带AA基因型的白血病或淋巴瘤患者，相比于AG或GG基因型，可能（1）治疗效果较差，（2）较...   2A  \n",
       "76  携带AG基因型的白血病或淋巴瘤患者，相比于GG基因型，可能（1）治疗效果较差，（2）较高的药...  NaN  \n",
       "78  携带GG基因型的白血病或淋巴瘤患者，相比于AA或AG基因型，可能（1）治疗效果较好，（2）有...  NaN  \n",
       "79  携带CC基因型的乳腺癌患者，相比于TT基因型，可能有（1）较低的但不消除的复发风险，（2）较...   2A  \n",
       "81  携带CT基因型的乳腺癌患者，相比于TT基因型，可能有（1）较低的但不消除的复发风险，（2）较...  NaN  \n",
       "82  携带TT基因型的乳腺癌患者，相比于CT或CC基因型，可能有（1）较高的复发风险，（2）较低发...  NaN  \n",
       "83  携带CC基因型的乳腺癌患者，相比于CG和GG基因型，可能有较高的芳香酶抑制剂相关的肌肉骨骼综...    3  \n",
       "85  携带CG基因型的乳腺癌患者，相比于CC基因型，可能有较低的芳香酶抑制剂相关的肌肉骨骼综合征，...  NaN  \n",
       "86  携带GG基因型的乳腺癌患者，相比于CC基因型，可能有较低的芳香酶抑制剂相关的肌肉骨骼综合征，...  NaN  \n",
       "87  携带AA基因型的乳腺癌患者，相比于AC和CC基因型，对于绝经前的女性，可能有较好的治疗效果。...   2B  \n",
       "89  携带AC基因型的乳腺癌患者，相比于AA基因型，对于绝经前的女性，可能有较差的治疗效果。对于绝...  NaN  \n",
       "90  携带CC基因型的乳腺癌患者，相比于AA基因型，对于绝经前的女性，可能有较差的治疗效果。对于绝...  NaN  \n",
       "91  携带CC基因型的绝经后激素受体（HR）阳性乳腺癌患者，相比于TT基因型，可能有较低的血管舒缩...    3  \n",
       "93  携带CT基因型的绝经后激素受体（HR）阳性乳腺癌患者，相比于TT基因型，可能有较低的血管舒缩...  NaN  \n",
       "94  携带TT基因型的绝经后激素受体（HR）阳性乳腺癌患者，相比于CC或CT基因型，可能有较高的血...  NaN  \n",
       "95           携带AA基因型的乳腺癌患者，相比于AG和GG基因型，可能有较低的骨密度流失风险。    3  \n",
       "97              携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较高的骨密度流失风险。  NaN  \n",
       "98              携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较高的骨密度流失风险。  NaN  \n",
       "\n",
       "[72 rows x 7 columns]"
      ]
     },
     "execution_count": 444,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 445,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/andy/.local/lib/python3.7/site-packages/ipykernel_launcher.py:14: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: http://pandas.pydata.org/pandas-docs/stable/indexing.html#indexing-view-versus-copy\n",
      "  \n"
     ]
    }
   ],
   "source": [
    "#填充nan值的函数\n",
    "def make_column(string):\n",
    "    a = ''\n",
    "    list1 = []\n",
    "    for i in df.index:\n",
    "        if type(df[string][i]) != type(df[string][2]):\n",
    "            a = df[string][i]\n",
    "            list1.append(a)\n",
    "        else:\n",
    "            list1.append(a)\n",
    "    return list1\n",
    "\n",
    "for i in ['化疗药物', '基因', '位点', '证据等级']:\n",
    "    df[i] = (make_column(i))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 446,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>化疗药物</th>\n",
       "      <th>基因</th>\n",
       "      <th>位点</th>\n",
       "      <th>基因型</th>\n",
       "      <th>类别</th>\n",
       "      <th>解释</th>\n",
       "      <th>证据等级</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>环磷酰胺+表柔比星</td>\n",
       "      <td>GSTP1</td>\n",
       "      <td>rs1695</td>\n",
       "      <td>AA</td>\n",
       "      <td>疗效较好，毒副较低</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于GG基因型，可能有1）较好的药物效果，2）较低的药物毒性风险。</td>\n",
       "      <td>2A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>环磷酰胺+表柔比星</td>\n",
       "      <td>GSTP1</td>\n",
       "      <td>rs1695</td>\n",
       "      <td>AG</td>\n",
       "      <td>疗效较好，毒副较低</td>\n",
       "      <td>携带AG基因型的乳腺癌患者，相比于GG基因型，可能有1）较好的药物效果，2）较低的药物毒性风险。</td>\n",
       "      <td>2A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>环磷酰胺+表柔比星</td>\n",
       "      <td>GSTP1</td>\n",
       "      <td>rs1695</td>\n",
       "      <td>GG</td>\n",
       "      <td>疗效较差，毒副较高</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于AG和AA基因型，可能有1）较差的药物效果，2）较高的药物...</td>\n",
       "      <td>2A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>环磷酰胺+多柔比星+氟尿嘧啶</td>\n",
       "      <td>ABCC4</td>\n",
       "      <td>rs9561778</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于GT和TT基因型，可能有较低但不消除的的药物不良反应风险。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>环磷酰胺+多柔比星+氟尿嘧啶</td>\n",
       "      <td>ABCC4</td>\n",
       "      <td>rs9561778</td>\n",
       "      <td>GT</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带GT基因型的乳腺癌患者，相比于GG基因型，可能有较高的药物不良反应风险。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>环磷酰胺+多柔比星+氟尿嘧啶</td>\n",
       "      <td>ABCC4</td>\n",
       "      <td>rs9561778</td>\n",
       "      <td>TT</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带TT基因型的乳腺癌患者，相比于GG基因型，可能有较高的药物不良反应风险。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>环磷酰胺+多柔比星+氟尿嘧啶</td>\n",
       "      <td>ERCC1</td>\n",
       "      <td>rs11615</td>\n",
       "      <td>AA</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于AG和GG基因型，可能有较低的贫血和肾毒性风险。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>环磷酰胺+多柔比星+氟尿嘧啶</td>\n",
       "      <td>ERCC1</td>\n",
       "      <td>rs11615</td>\n",
       "      <td>AG</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较高的贫血和肾毒性风险。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>环磷酰胺+多柔比星+氟尿嘧啶</td>\n",
       "      <td>ERCC1</td>\n",
       "      <td>rs11615</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较高的贫血和肾毒性风险。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>多柔比星</td>\n",
       "      <td>CBR3</td>\n",
       "      <td>rs8133052</td>\n",
       "      <td>AA</td>\n",
       "      <td>疗效较好，毒副较高</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于GG基因型，可能有1）较慢的药物代谢，2）较大程度的肿瘤缩...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>多柔比星</td>\n",
       "      <td>CBR3</td>\n",
       "      <td>rs8133052</td>\n",
       "      <td>AG</td>\n",
       "      <td>疗效适中，毒副适中</td>\n",
       "      <td>携带AG基因型的乳腺癌患者，相比于GG基因型，可能有1）较慢的药物代谢，2）较大程度的肿瘤缩...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>多柔比星</td>\n",
       "      <td>CBR3</td>\n",
       "      <td>rs8133052</td>\n",
       "      <td>GG</td>\n",
       "      <td>疗效较差，毒副较低</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于AA基因型，可能有1）较快的药物代谢，2）较小程度的肿瘤缩...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>环磷酰胺</td>\n",
       "      <td>SOD2</td>\n",
       "      <td>rs4880</td>\n",
       "      <td>AA</td>\n",
       "      <td>疗效较好</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于GG基因型，可能有较长的生存期。</td>\n",
       "      <td>2B</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>环磷酰胺</td>\n",
       "      <td>SOD2</td>\n",
       "      <td>rs4880</td>\n",
       "      <td>AG</td>\n",
       "      <td>疗效适中</td>\n",
       "      <td>携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较短的生存期。相比于GG基因型，可能有较...</td>\n",
       "      <td>2B</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>环磷酰胺</td>\n",
       "      <td>SOD2</td>\n",
       "      <td>rs4880</td>\n",
       "      <td>GG</td>\n",
       "      <td>疗效较差</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较短的生存期。</td>\n",
       "      <td>2B</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>环磷酰胺</td>\n",
       "      <td>ABCC4</td>\n",
       "      <td>rs9561778</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于TT基因型，可能有较低但不消除的药物毒副风险，尤其是嗜中性...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>环磷酰胺</td>\n",
       "      <td>ABCC4</td>\n",
       "      <td>rs9561778</td>\n",
       "      <td>GT</td>\n",
       "      <td>毒副适中</td>\n",
       "      <td>携带GT基因型的乳腺癌患者，相比于GG基因型，可能有较高的药物毒副风险，尤其是嗜中性白血球减...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>环磷酰胺</td>\n",
       "      <td>ABCC4</td>\n",
       "      <td>rs9561778</td>\n",
       "      <td>TT</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带TT基因型的乳腺癌患者，相比于GT基因型，可能有较高的药物毒副风险，尤其是嗜中性白血球减...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>紫杉醇</td>\n",
       "      <td>SOD2</td>\n",
       "      <td>rs4880</td>\n",
       "      <td>AA</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于AG或GG基因型，可能有较高的神经病变风险，这种相关性只见...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>紫杉醇</td>\n",
       "      <td>SOD2</td>\n",
       "      <td>rs4880</td>\n",
       "      <td>AG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较低的神经病变风险，这种相关性只见于CY...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>紫杉醇</td>\n",
       "      <td>SOD2</td>\n",
       "      <td>rs4880</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较低的神经病变风险，这种相关性只见于CY...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>紫杉醇</td>\n",
       "      <td>ABCB1</td>\n",
       "      <td>rs1045642</td>\n",
       "      <td>AA</td>\n",
       "      <td>疗效较差</td>\n",
       "      <td>携带AA基因型的转移性乳腺癌患者，相比于GG基因型，可能有较低的疾病控制率和较低的总生存率。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>紫杉醇</td>\n",
       "      <td>ABCB1</td>\n",
       "      <td>rs1045642</td>\n",
       "      <td>AG</td>\n",
       "      <td>疗效较差</td>\n",
       "      <td>携带AG基因型的转移性乳腺癌患者，相比于GG基因型，可能有较低的疾病控制率和较低的总生存率。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>紫杉醇</td>\n",
       "      <td>ABCB1</td>\n",
       "      <td>rs1045642</td>\n",
       "      <td>GG</td>\n",
       "      <td>疗效较好</td>\n",
       "      <td>携带GG基因型的转移性乳腺癌患者，相比于AG基因型，可能有较高的疾病控制率和较高的总生存率。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>多西他赛</td>\n",
       "      <td>ERCC2</td>\n",
       "      <td>rs13181</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于TT基因型，可能有较低的嗜中性白血球减少症的风险，但在肌病...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>多西他赛</td>\n",
       "      <td>ERCC2</td>\n",
       "      <td>rs13181</td>\n",
       "      <td>GT</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带GT基因型的乳腺癌患者，相比于TT基因型，可能有较低的嗜中性白血球减少症的风险，但在肌病...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>多西他赛</td>\n",
       "      <td>ERCC2</td>\n",
       "      <td>rs13181</td>\n",
       "      <td>TT</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带TT基因型的乳腺癌患者，相比于GG或GT基因型，可能有较高的嗜中性白血球减少症的风险，但...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>多西他赛</td>\n",
       "      <td>VEGFA</td>\n",
       "      <td>rs699947</td>\n",
       "      <td>AA</td>\n",
       "      <td>疗效较好</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于CC基因型，可能有较长的无进展生存期。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>多西他赛</td>\n",
       "      <td>VEGFA</td>\n",
       "      <td>rs699947</td>\n",
       "      <td>AC</td>\n",
       "      <td>疗效适中</td>\n",
       "      <td>未有研究发现</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>多西他赛</td>\n",
       "      <td>VEGFA</td>\n",
       "      <td>rs699947</td>\n",
       "      <td>CC</td>\n",
       "      <td>疗效较差</td>\n",
       "      <td>携带CC基因型的乳腺癌患者，相比于AA基因型，可能有较短的无进展生存期。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>卡培他滨、氟尿嘧啶</td>\n",
       "      <td>TYMS</td>\n",
       "      <td>rs151264360</td>\n",
       "      <td>TTAAAG/TTAAAG</td>\n",
       "      <td>疗效较差，毒副较低</td>\n",
       "      <td>携带TTAAAG/TTAAAG基因型的肿瘤患者，相比于TTAAAG/del 或del/del...</td>\n",
       "      <td>2A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>60</th>\n",
       "      <td>卡培他滨、氟尿嘧啶</td>\n",
       "      <td>TYMS</td>\n",
       "      <td>rs151264360</td>\n",
       "      <td>TTAAAG/del</td>\n",
       "      <td>疗效适中，毒副适中</td>\n",
       "      <td>携带TTAAAG/del基因型的肿瘤患者，相比于TTAAAG/TTAAAG基因型，可能有较长...</td>\n",
       "      <td>2A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>61</th>\n",
       "      <td>卡培他滨、氟尿嘧啶</td>\n",
       "      <td>TYMS</td>\n",
       "      <td>rs151264360</td>\n",
       "      <td>(-/-)</td>\n",
       "      <td>疗效较好，毒副较高</td>\n",
       "      <td>携带del/del基因型的肿瘤患者，相比于TTAAAG/TTAAAG或TTAAAG/del基...</td>\n",
       "      <td>2A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>62</th>\n",
       "      <td>吉西他滨</td>\n",
       "      <td>RRM1</td>\n",
       "      <td>rs1042858</td>\n",
       "      <td>AA</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带AA基因型且在rs9937位点携带G等位基因的乳腺癌患者，相比于GG基因型，可能会降低毒...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>64</th>\n",
       "      <td>吉西他滨</td>\n",
       "      <td>RRM1</td>\n",
       "      <td>rs1042858</td>\n",
       "      <td>AG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带AG基因型且在rs9937位点携带G等位基因的乳腺癌患者，相比于GG基因型，可能会降低毒...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>65</th>\n",
       "      <td>吉西他滨</td>\n",
       "      <td>RRM1</td>\n",
       "      <td>rs1042858</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带GG基因型且在rs9937位点携带G等位基因的乳腺癌患者，相比于AA或AG基因型，可能会...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>66</th>\n",
       "      <td>吉西他滨</td>\n",
       "      <td>RRM1</td>\n",
       "      <td>rs9937</td>\n",
       "      <td>AA</td>\n",
       "      <td>疗效较差，毒副较高</td>\n",
       "      <td>携带AA基因型的肿瘤患者，相比于AG或GG基因型，可能有（1）较高风险发生嗜中性白血球减少症...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>68</th>\n",
       "      <td>吉西他滨</td>\n",
       "      <td>RRM1</td>\n",
       "      <td>rs9937</td>\n",
       "      <td>AG</td>\n",
       "      <td>疗效较好，毒副较低</td>\n",
       "      <td>携带AG基因型的肿瘤患者，相比于AA基因型，可能有（1）较低风险发生嗜中性白血球减少症，（2...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>69</th>\n",
       "      <td>吉西他滨</td>\n",
       "      <td>RRM1</td>\n",
       "      <td>rs9937</td>\n",
       "      <td>GG</td>\n",
       "      <td>疗效较好，毒副较低</td>\n",
       "      <td>携带GG基因型的肿瘤患者，相比于AA基因型，可能有（1）较低风险发生嗜中性白血球减少症，（2...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>70</th>\n",
       "      <td>吉西他滨</td>\n",
       "      <td>NT5C2</td>\n",
       "      <td>rs11598702</td>\n",
       "      <td>CC</td>\n",
       "      <td>代谢较快</td>\n",
       "      <td>携带CC基因型的肿瘤患者，相比于TT基因型，可能有较高的药物清除。</td>\n",
       "      <td>2B</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>72</th>\n",
       "      <td>吉西他滨</td>\n",
       "      <td>NT5C2</td>\n",
       "      <td>rs11598702</td>\n",
       "      <td>CT</td>\n",
       "      <td>代谢较快</td>\n",
       "      <td>携带CT基因型的肿瘤患者，相比于TT基因型，可能有较高的药物清除。</td>\n",
       "      <td>2B</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>73</th>\n",
       "      <td>吉西他滨</td>\n",
       "      <td>NT5C2</td>\n",
       "      <td>rs11598702</td>\n",
       "      <td>TT</td>\n",
       "      <td>代谢较慢</td>\n",
       "      <td>携带TT基因型的肿瘤患者，相比于CT和CC基因型，可能有较低的药物清除。</td>\n",
       "      <td>2B</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>74</th>\n",
       "      <td>甲氨蝶呤</td>\n",
       "      <td>MTHFR</td>\n",
       "      <td>rs1801133</td>\n",
       "      <td>AA</td>\n",
       "      <td>疗效较差，毒副较高</td>\n",
       "      <td>携带AA基因型的白血病或淋巴瘤患者，相比于AG或GG基因型，可能（1）治疗效果较差，（2）较...</td>\n",
       "      <td>2A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>76</th>\n",
       "      <td>甲氨蝶呤</td>\n",
       "      <td>MTHFR</td>\n",
       "      <td>rs1801133</td>\n",
       "      <td>AG</td>\n",
       "      <td>疗效适中，毒副适中</td>\n",
       "      <td>携带AG基因型的白血病或淋巴瘤患者，相比于GG基因型，可能（1）治疗效果较差，（2）较高的药...</td>\n",
       "      <td>2A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>78</th>\n",
       "      <td>甲氨蝶呤</td>\n",
       "      <td>MTHFR</td>\n",
       "      <td>rs1801133</td>\n",
       "      <td>GG</td>\n",
       "      <td>疗效较好，毒副较低</td>\n",
       "      <td>携带GG基因型的白血病或淋巴瘤患者，相比于AA或AG基因型，可能（1）治疗效果较好，（2）有...</td>\n",
       "      <td>2A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>79</th>\n",
       "      <td>他莫昔芬</td>\n",
       "      <td>CYP2D6</td>\n",
       "      <td>rs3892097</td>\n",
       "      <td>CC</td>\n",
       "      <td>疗效较好，毒副较高</td>\n",
       "      <td>携带CC基因型的乳腺癌患者，相比于TT基因型，可能有（1）较低的但不消除的复发风险，（2）较...</td>\n",
       "      <td>2A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>81</th>\n",
       "      <td>他莫昔芬</td>\n",
       "      <td>CYP2D6</td>\n",
       "      <td>rs3892097</td>\n",
       "      <td>CT</td>\n",
       "      <td>疗效较好，毒副较高</td>\n",
       "      <td>携带CT基因型的乳腺癌患者，相比于TT基因型，可能有（1）较低的但不消除的复发风险，（2）较...</td>\n",
       "      <td>2A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>82</th>\n",
       "      <td>他莫昔芬</td>\n",
       "      <td>CYP2D6</td>\n",
       "      <td>rs3892097</td>\n",
       "      <td>TT</td>\n",
       "      <td>疗效较差，毒副较低</td>\n",
       "      <td>携带TT基因型的乳腺癌患者，相比于CT或CC基因型，可能有（1）较高的复发风险，（2）较低发...</td>\n",
       "      <td>2A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>来曲唑、阿那曲唑</td>\n",
       "      <td>TNFSF11</td>\n",
       "      <td>rs7984870</td>\n",
       "      <td>CC</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带CC基因型的乳腺癌患者，相比于CG和GG基因型，可能有较高的芳香酶抑制剂相关的肌肉骨骼综...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>来曲唑、阿那曲唑</td>\n",
       "      <td>TNFSF11</td>\n",
       "      <td>rs7984870</td>\n",
       "      <td>CG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带CG基因型的乳腺癌患者，相比于CC基因型，可能有较低的芳香酶抑制剂相关的肌肉骨骼综合征，...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>来曲唑、阿那曲唑</td>\n",
       "      <td>TNFSF11</td>\n",
       "      <td>rs7984870</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于CC基因型，可能有较低的芳香酶抑制剂相关的肌肉骨骼综合征，...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>来曲唑、阿那曲唑</td>\n",
       "      <td>CYP19A1</td>\n",
       "      <td>rs4646</td>\n",
       "      <td>AA</td>\n",
       "      <td>绝经前疗效较好，绝经后疗效较差</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于AC和CC基因型，对于绝经前的女性，可能有较好的治疗效果。...</td>\n",
       "      <td>2B</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>89</th>\n",
       "      <td>来曲唑、阿那曲唑</td>\n",
       "      <td>CYP19A1</td>\n",
       "      <td>rs4646</td>\n",
       "      <td>AC</td>\n",
       "      <td>绝经前疗效较差，绝经后疗效较好</td>\n",
       "      <td>携带AC基因型的乳腺癌患者，相比于AA基因型，对于绝经前的女性，可能有较差的治疗效果。对于绝...</td>\n",
       "      <td>2B</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>90</th>\n",
       "      <td>来曲唑、阿那曲唑</td>\n",
       "      <td>CYP19A1</td>\n",
       "      <td>rs4646</td>\n",
       "      <td>CC</td>\n",
       "      <td>绝经前疗效较差，绝经后疗效较好</td>\n",
       "      <td>携带CC基因型的乳腺癌患者，相比于AA基因型，对于绝经前的女性，可能有较差的治疗效果。对于绝...</td>\n",
       "      <td>2B</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>91</th>\n",
       "      <td>依西美坦</td>\n",
       "      <td>CYP19A1</td>\n",
       "      <td>rs7176005</td>\n",
       "      <td>CC</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带CC基因型的绝经后激素受体（HR）阳性乳腺癌患者，相比于TT基因型，可能有较低的血管舒缩...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>93</th>\n",
       "      <td>依西美坦</td>\n",
       "      <td>CYP19A1</td>\n",
       "      <td>rs7176005</td>\n",
       "      <td>CT</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带CT基因型的绝经后激素受体（HR）阳性乳腺癌患者，相比于TT基因型，可能有较低的血管舒缩...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>94</th>\n",
       "      <td>依西美坦</td>\n",
       "      <td>CYP19A1</td>\n",
       "      <td>rs7176005</td>\n",
       "      <td>TT</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带TT基因型的绝经后激素受体（HR）阳性乳腺癌患者，相比于CC或CT基因型，可能有较高的血...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>依西美坦</td>\n",
       "      <td>ESR1</td>\n",
       "      <td>rs2813543</td>\n",
       "      <td>AA</td>\n",
       "      <td>毒副较低</td>\n",
       "      <td>携带AA基因型的乳腺癌患者，相比于AG和GG基因型，可能有较低的骨密度流失风险。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>依西美坦</td>\n",
       "      <td>ESR1</td>\n",
       "      <td>rs2813543</td>\n",
       "      <td>AG</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较高的骨密度流失风险。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>98</th>\n",
       "      <td>依西美坦</td>\n",
       "      <td>ESR1</td>\n",
       "      <td>rs2813543</td>\n",
       "      <td>GG</td>\n",
       "      <td>毒副较高</td>\n",
       "      <td>携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较高的骨密度流失风险。</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>72 rows × 7 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "              化疗药物       基因           位点            基因型               类别  \\\n",
       "0        环磷酰胺+表柔比星    GSTP1       rs1695             AA        疗效较好，毒副较低   \n",
       "1        环磷酰胺+表柔比星    GSTP1       rs1695             AG        疗效较好，毒副较低   \n",
       "2        环磷酰胺+表柔比星    GSTP1       rs1695             GG        疗效较差，毒副较高   \n",
       "3   环磷酰胺+多柔比星+氟尿嘧啶    ABCC4    rs9561778             GG             毒副较低   \n",
       "5   环磷酰胺+多柔比星+氟尿嘧啶    ABCC4    rs9561778             GT             毒副较高   \n",
       "6   环磷酰胺+多柔比星+氟尿嘧啶    ABCC4    rs9561778             TT             毒副较高   \n",
       "7   环磷酰胺+多柔比星+氟尿嘧啶    ERCC1      rs11615             AA             毒副较低   \n",
       "9   环磷酰胺+多柔比星+氟尿嘧啶    ERCC1      rs11615             AG             毒副较高   \n",
       "10  环磷酰胺+多柔比星+氟尿嘧啶    ERCC1      rs11615             GG             毒副较高   \n",
       "11            多柔比星     CBR3    rs8133052             AA        疗效较好，毒副较高   \n",
       "13            多柔比星     CBR3    rs8133052             AG        疗效适中，毒副适中   \n",
       "16            多柔比星     CBR3    rs8133052             GG        疗效较差，毒副较低   \n",
       "17            环磷酰胺     SOD2       rs4880             AA             疗效较好   \n",
       "19            环磷酰胺     SOD2       rs4880             AG             疗效适中   \n",
       "20            环磷酰胺     SOD2       rs4880             GG             疗效较差   \n",
       "21            环磷酰胺    ABCC4    rs9561778             GG             毒副较低   \n",
       "23            环磷酰胺    ABCC4    rs9561778             GT             毒副适中   \n",
       "24            环磷酰胺    ABCC4    rs9561778             TT             毒副较高   \n",
       "25             紫杉醇     SOD2       rs4880             AA             毒副较高   \n",
       "27             紫杉醇     SOD2       rs4880             AG             毒副较低   \n",
       "28             紫杉醇     SOD2       rs4880             GG             毒副较低   \n",
       "29             紫杉醇    ABCB1    rs1045642             AA             疗效较差   \n",
       "31             紫杉醇    ABCB1    rs1045642             AG             疗效较差   \n",
       "32             紫杉醇    ABCB1    rs1045642             GG             疗效较好   \n",
       "33            多西他赛    ERCC2      rs13181             GG             毒副较低   \n",
       "35            多西他赛    ERCC2      rs13181             GT             毒副较低   \n",
       "36            多西他赛    ERCC2      rs13181             TT             毒副较高   \n",
       "37            多西他赛    VEGFA     rs699947             AA             疗效较好   \n",
       "39            多西他赛    VEGFA     rs699947             AC             疗效适中   \n",
       "40            多西他赛    VEGFA     rs699947             CC             疗效较差   \n",
       "..             ...      ...          ...            ...              ...   \n",
       "58       卡培他滨、氟尿嘧啶     TYMS  rs151264360  TTAAAG/TTAAAG        疗效较差，毒副较低   \n",
       "60       卡培他滨、氟尿嘧啶     TYMS  rs151264360     TTAAAG/del        疗效适中，毒副适中   \n",
       "61       卡培他滨、氟尿嘧啶     TYMS  rs151264360          (-/-)        疗效较好，毒副较高   \n",
       "62            吉西他滨     RRM1    rs1042858             AA             毒副较低   \n",
       "64            吉西他滨     RRM1    rs1042858             AG             毒副较低   \n",
       "65            吉西他滨     RRM1    rs1042858             GG             毒副较高   \n",
       "66            吉西他滨     RRM1       rs9937             AA        疗效较差，毒副较高   \n",
       "68            吉西他滨     RRM1       rs9937             AG        疗效较好，毒副较低   \n",
       "69            吉西他滨     RRM1       rs9937             GG        疗效较好，毒副较低   \n",
       "70            吉西他滨    NT5C2   rs11598702             CC             代谢较快   \n",
       "72            吉西他滨    NT5C2   rs11598702             CT             代谢较快   \n",
       "73            吉西他滨    NT5C2   rs11598702             TT             代谢较慢   \n",
       "74            甲氨蝶呤    MTHFR    rs1801133             AA        疗效较差，毒副较高   \n",
       "76            甲氨蝶呤    MTHFR    rs1801133             AG        疗效适中，毒副适中   \n",
       "78            甲氨蝶呤    MTHFR    rs1801133             GG        疗效较好，毒副较低   \n",
       "79            他莫昔芬   CYP2D6    rs3892097             CC        疗效较好，毒副较高   \n",
       "81            他莫昔芬   CYP2D6    rs3892097             CT        疗效较好，毒副较高   \n",
       "82            他莫昔芬   CYP2D6    rs3892097             TT        疗效较差，毒副较低   \n",
       "83        来曲唑、阿那曲唑  TNFSF11    rs7984870             CC             毒副较高   \n",
       "85        来曲唑、阿那曲唑  TNFSF11    rs7984870             CG             毒副较低   \n",
       "86        来曲唑、阿那曲唑  TNFSF11    rs7984870             GG             毒副较低   \n",
       "87        来曲唑、阿那曲唑  CYP19A1       rs4646             AA  绝经前疗效较好，绝经后疗效较差   \n",
       "89        来曲唑、阿那曲唑  CYP19A1       rs4646             AC  绝经前疗效较差，绝经后疗效较好   \n",
       "90        来曲唑、阿那曲唑  CYP19A1       rs4646             CC  绝经前疗效较差，绝经后疗效较好   \n",
       "91            依西美坦  CYP19A1    rs7176005             CC             毒副较低   \n",
       "93            依西美坦  CYP19A1    rs7176005             CT             毒副较低   \n",
       "94            依西美坦  CYP19A1    rs7176005             TT             毒副较高   \n",
       "95            依西美坦     ESR1    rs2813543             AA             毒副较低   \n",
       "97            依西美坦     ESR1    rs2813543             AG             毒副较高   \n",
       "98            依西美坦     ESR1    rs2813543             GG             毒副较高   \n",
       "\n",
       "                                                   解释 证据等级  \n",
       "0    携带AA基因型的乳腺癌患者，相比于GG基因型，可能有1）较好的药物效果，2）较低的药物毒性风险。   2A  \n",
       "1    携带AG基因型的乳腺癌患者，相比于GG基因型，可能有1）较好的药物效果，2）较低的药物毒性风险。   2A  \n",
       "2   携带GG基因型的乳腺癌患者，相比于AG和AA基因型，可能有1）较差的药物效果，2）较高的药物...   2A  \n",
       "3      携带GG基因型的乳腺癌患者，相比于GT和TT基因型，可能有较低但不消除的的药物不良反应风险。    3  \n",
       "5              携带GT基因型的乳腺癌患者，相比于GG基因型，可能有较高的药物不良反应风险。    3  \n",
       "6              携带TT基因型的乳腺癌患者，相比于GG基因型，可能有较高的药物不良反应风险。    3  \n",
       "7           携带AA基因型的乳腺癌患者，相比于AG和GG基因型，可能有较低的贫血和肾毒性风险。    3  \n",
       "9              携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较高的贫血和肾毒性风险。    3  \n",
       "10             携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较高的贫血和肾毒性风险。    3  \n",
       "11  携带AA基因型的乳腺癌患者，相比于GG基因型，可能有1）较慢的药物代谢，2）较大程度的肿瘤缩...    3  \n",
       "13  携带AG基因型的乳腺癌患者，相比于GG基因型，可能有1）较慢的药物代谢，2）较大程度的肿瘤缩...    3  \n",
       "16  携带GG基因型的乳腺癌患者，相比于AA基因型，可能有1）较快的药物代谢，2）较小程度的肿瘤缩...    3  \n",
       "17                  携带AA基因型的乳腺癌患者，相比于GG基因型，可能有较长的生存期。   2B  \n",
       "19  携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较短的生存期。相比于GG基因型，可能有较...   2B  \n",
       "20                  携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较短的生存期。   2B  \n",
       "21  携带GG基因型的乳腺癌患者，相比于TT基因型，可能有较低但不消除的药物毒副风险，尤其是嗜中性...    3  \n",
       "23  携带GT基因型的乳腺癌患者，相比于GG基因型，可能有较高的药物毒副风险，尤其是嗜中性白血球减...    3  \n",
       "24  携带TT基因型的乳腺癌患者，相比于GT基因型，可能有较高的药物毒副风险，尤其是嗜中性白血球减...    3  \n",
       "25  携带AA基因型的乳腺癌患者，相比于AG或GG基因型，可能有较高的神经病变风险，这种相关性只见...    3  \n",
       "27  携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较低的神经病变风险，这种相关性只见于CY...    3  \n",
       "28  携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较低的神经病变风险，这种相关性只见于CY...    3  \n",
       "29     携带AA基因型的转移性乳腺癌患者，相比于GG基因型，可能有较低的疾病控制率和较低的总生存率。    3  \n",
       "31     携带AG基因型的转移性乳腺癌患者，相比于GG基因型，可能有较低的疾病控制率和较低的总生存率。    3  \n",
       "32     携带GG基因型的转移性乳腺癌患者，相比于AG基因型，可能有较高的疾病控制率和较高的总生存率。    3  \n",
       "33  携带GG基因型的乳腺癌患者，相比于TT基因型，可能有较低的嗜中性白血球减少症的风险，但在肌病...    3  \n",
       "35  携带GT基因型的乳腺癌患者，相比于TT基因型，可能有较低的嗜中性白血球减少症的风险，但在肌病...    3  \n",
       "36  携带TT基因型的乳腺癌患者，相比于GG或GT基因型，可能有较高的嗜中性白血球减少症的风险，但...    3  \n",
       "37               携带AA基因型的乳腺癌患者，相比于CC基因型，可能有较长的无进展生存期。    3  \n",
       "39                                             未有研究发现    3  \n",
       "40               携带CC基因型的乳腺癌患者，相比于AA基因型，可能有较短的无进展生存期。    3  \n",
       "..                                                ...  ...  \n",
       "58  携带TTAAAG/TTAAAG基因型的肿瘤患者，相比于TTAAAG/del 或del/del...   2A  \n",
       "60  携带TTAAAG/del基因型的肿瘤患者，相比于TTAAAG/TTAAAG基因型，可能有较长...   2A  \n",
       "61  携带del/del基因型的肿瘤患者，相比于TTAAAG/TTAAAG或TTAAAG/del基...   2A  \n",
       "62  携带AA基因型且在rs9937位点携带G等位基因的乳腺癌患者，相比于GG基因型，可能会降低毒...    3  \n",
       "64  携带AG基因型且在rs9937位点携带G等位基因的乳腺癌患者，相比于GG基因型，可能会降低毒...    3  \n",
       "65  携带GG基因型且在rs9937位点携带G等位基因的乳腺癌患者，相比于AA或AG基因型，可能会...    3  \n",
       "66  携带AA基因型的肿瘤患者，相比于AG或GG基因型，可能有（1）较高风险发生嗜中性白血球减少症...    3  \n",
       "68  携带AG基因型的肿瘤患者，相比于AA基因型，可能有（1）较低风险发生嗜中性白血球减少症，（2...    3  \n",
       "69  携带GG基因型的肿瘤患者，相比于AA基因型，可能有（1）较低风险发生嗜中性白血球减少症，（2...    3  \n",
       "70                  携带CC基因型的肿瘤患者，相比于TT基因型，可能有较高的药物清除。   2B  \n",
       "72                  携带CT基因型的肿瘤患者，相比于TT基因型，可能有较高的药物清除。   2B  \n",
       "73               携带TT基因型的肿瘤患者，相比于CT和CC基因型，可能有较低的药物清除。   2B  \n",
       "74  携带AA基因型的白血病或淋巴瘤患者，相比于AG或GG基因型，可能（1）治疗效果较差，（2）较...   2A  \n",
       "76  携带AG基因型的白血病或淋巴瘤患者，相比于GG基因型，可能（1）治疗效果较差，（2）较高的药...   2A  \n",
       "78  携带GG基因型的白血病或淋巴瘤患者，相比于AA或AG基因型，可能（1）治疗效果较好，（2）有...   2A  \n",
       "79  携带CC基因型的乳腺癌患者，相比于TT基因型，可能有（1）较低的但不消除的复发风险，（2）较...   2A  \n",
       "81  携带CT基因型的乳腺癌患者，相比于TT基因型，可能有（1）较低的但不消除的复发风险，（2）较...   2A  \n",
       "82  携带TT基因型的乳腺癌患者，相比于CT或CC基因型，可能有（1）较高的复发风险，（2）较低发...   2A  \n",
       "83  携带CC基因型的乳腺癌患者，相比于CG和GG基因型，可能有较高的芳香酶抑制剂相关的肌肉骨骼综...    3  \n",
       "85  携带CG基因型的乳腺癌患者，相比于CC基因型，可能有较低的芳香酶抑制剂相关的肌肉骨骼综合征，...    3  \n",
       "86  携带GG基因型的乳腺癌患者，相比于CC基因型，可能有较低的芳香酶抑制剂相关的肌肉骨骼综合征，...    3  \n",
       "87  携带AA基因型的乳腺癌患者，相比于AC和CC基因型，对于绝经前的女性，可能有较好的治疗效果。...   2B  \n",
       "89  携带AC基因型的乳腺癌患者，相比于AA基因型，对于绝经前的女性，可能有较差的治疗效果。对于绝...   2B  \n",
       "90  携带CC基因型的乳腺癌患者，相比于AA基因型，对于绝经前的女性，可能有较差的治疗效果。对于绝...   2B  \n",
       "91  携带CC基因型的绝经后激素受体（HR）阳性乳腺癌患者，相比于TT基因型，可能有较低的血管舒缩...    3  \n",
       "93  携带CT基因型的绝经后激素受体（HR）阳性乳腺癌患者，相比于TT基因型，可能有较低的血管舒缩...    3  \n",
       "94  携带TT基因型的绝经后激素受体（HR）阳性乳腺癌患者，相比于CC或CT基因型，可能有较高的血...    3  \n",
       "95           携带AA基因型的乳腺癌患者，相比于AG和GG基因型，可能有较低的骨密度流失风险。    3  \n",
       "97              携带AG基因型的乳腺癌患者，相比于AA基因型，可能有较高的骨密度流失风险。    3  \n",
       "98              携带GG基因型的乳腺癌患者，相比于AA基因型，可能有较高的骨密度流失风险。    3  \n",
       "\n",
       "[72 rows x 7 columns]"
      ]
     },
     "execution_count": 446,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 447,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'环磷酰胺+表柔比星\\tGSTP1\\trs1695': {}, '环磷酰胺+多柔比星+氟尿嘧啶\\tABCC4\\trs9561778': {}, '环磷酰胺+多柔比星+氟尿嘧啶\\tERCC1\\trs11615': {}, '多柔比星\\tCBR3\\trs8133052': {}, '环磷酰胺\\tSOD2\\trs4880': {}, '环磷酰胺\\tABCC4\\trs9561778': {}, '紫杉醇\\tSOD2\\trs4880': {}, '紫杉醇\\tABCB1\\trs1045642': {}, '多西他赛\\tERCC2\\trs13181': {}, '多西他赛\\tVEGFA\\trs699947': {}, '顺铂、卡铂\\tERCC1\\trs11615': {}, '顺铂、卡铂\\tMTHFR\\trs1801133': {}, '卡培他滨、氟尿嘧啶\\tDPYD\\trs3918290': {}, '卡培他滨、氟尿嘧啶\\tDPYD\\trs67376798': {}, '卡培他滨、氟尿嘧啶\\tTYMS\\trs151264360': {}, '吉西他滨\\tRRM1\\trs1042858': {}, '吉西他滨\\tRRM1\\trs9937': {}, '吉西他滨\\tNT5C2\\trs11598702': {}, '甲氨蝶呤\\tMTHFR\\trs1801133': {}, '他莫昔芬\\tCYP2D6\\trs3892097': {}, '来曲唑、阿那曲唑\\tTNFSF11\\trs7984870': {}, '来曲唑、阿那曲唑\\tCYP19A1\\trs4646': {}, '依西美坦\\tCYP19A1\\trs7176005': {}, '依西美坦\\tESR1\\trs2813543': {}}\n"
     ]
    }
   ],
   "source": [
    "dic = {}\n",
    "dic1 = {}\n",
    "for i in df.index:\n",
    "    dic.setdefault(df['化疗药物'][i] + '\\t' + df['基因'][i] + '\\t' + df['位点'][i], {})\n",
    "    dic1.setdefault(df['化疗药物'][i] + '\\t' + df['基因'][i] + '\\t' + df['位点'][i], {})\n",
    "    \n",
    "print(dic1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 448,
   "metadata": {},
   "outputs": [],
   "source": [
    "for i in df.index:\n",
    "    dic[df['化疗药物'][i] + '\\t' + df['基因'][i] + '\\t' + df['位点'][i]][df['基因型'][i]] = df['解释'][i]\n",
    "    dic1[df['化疗药物'][i] + '\\t' + df['基因'][i] + '\\t' + df['位点'][i]][df['基因型'][i]] = df['类别'][i]\n",
    "    dic1[df['化疗药物'][i] + '\\t' + df['基因'][i] + '\\t' + df['位点'][i]]['证据等级'] = df['证据等级'][i]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 449,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'环磷酰胺+表柔比星\\tGSTP1\\trs1695': {'AA': '疗效较好，毒副较低', '证据等级': '2A', 'AG': '疗效较好，毒副较低', 'GG': '疗效较差，毒副较高'}, '环磷酰胺+多柔比星+氟尿嘧啶\\tABCC4\\trs9561778': {'GG': '毒副较低', '证据等级': 3, 'GT': '毒副较高', 'TT': '毒副较高'}, '环磷酰胺+多柔比星+氟尿嘧啶\\tERCC1\\trs11615': {'AA': '毒副较低', '证据等级': 3, 'AG': '毒副较高', 'GG': '毒副较高'}, '多柔比星\\tCBR3\\trs8133052': {'AA': '疗效较好，毒副较高', '证据等级': 3, 'AG': '疗效适中，毒副适中', 'GG': '疗效较差，毒副较低'}, '环磷酰胺\\tSOD2\\trs4880': {'AA': '疗效较好', '证据等级': '2B', 'AG': '疗效适中', 'GG': '疗效较差'}, '环磷酰胺\\tABCC4\\trs9561778': {'GG': '毒副较低', '证据等级': 3, 'GT': '毒副适中', 'TT': '毒副较高'}, '紫杉醇\\tSOD2\\trs4880': {'AA': '毒副较高', '证据等级': 3, 'AG': '毒副较低', 'GG': '毒副较低'}, '紫杉醇\\tABCB1\\trs1045642': {'AA': '疗效较差', '证据等级': 3, 'AG': '疗效较差', 'GG': '疗效较好'}, '多西他赛\\tERCC2\\trs13181': {'GG': '毒副较低', '证据等级': 3, 'GT': '毒副较低', 'TT': '毒副较高'}, '多西他赛\\tVEGFA\\trs699947': {'AA': '疗效较好', '证据等级': 3, 'AC': '疗效适中', 'CC': '疗效较差'}, '顺铂、卡铂\\tERCC1\\trs11615': {'AA': '疗效较差，毒副较高', '证据等级': '2B', 'AG': '疗效适中，毒副适中', 'GG': '疗效较好，毒副较低'}, '顺铂、卡铂\\tMTHFR\\trs1801133': {'AA': '疗效较好，毒副较高', '证据等级': '2A', 'AG': '疗效较差，毒副较低', 'GG': '疗效较差，毒副较低'}, '卡培他滨、氟尿嘧啶\\tDPYD\\trs3918290': {'CC': '代谢较快，毒副较低', '证据等级': '1A', 'CT': '代谢较慢，毒副较高', 'TT': '代谢较慢，毒副较高'}, '卡培他滨、氟尿嘧啶\\tDPYD\\trs67376798': {'AA': '毒副较高，代谢较慢', '证据等级': '1A', 'AT': '毒副较高，代谢较慢', 'TT': '毒副较低，代谢较快'}, '卡培他滨、氟尿嘧啶\\tTYMS\\trs151264360': {'TTAAAG/TTAAAG': '疗效较差，毒副较低', '证据等级': '2A', 'TTAAAG/del': '疗效适中，毒副适中', '(-/-)': '疗效较好，毒副较高'}, '吉西他滨\\tRRM1\\trs1042858': {'AA': '毒副较低', '证据等级': 3, 'AG': '毒副较低', 'GG': '毒副较高'}, '吉西他滨\\tRRM1\\trs9937': {'AA': '疗效较差，毒副较高', '证据等级': 3, 'AG': '疗效较好，毒副较低', 'GG': '疗效较好，毒副较低'}, '吉西他滨\\tNT5C2\\trs11598702': {'CC': '代谢较快', '证据等级': '2B', 'CT': '代谢较快', 'TT': '代谢较慢'}, '甲氨蝶呤\\tMTHFR\\trs1801133': {'AA': '疗效较差，毒副较高', '证据等级': '2A', 'AG': '疗效适中，毒副适中', 'GG': '疗效较好，毒副较低'}, '他莫昔芬\\tCYP2D6\\trs3892097': {'CC': '疗效较好，毒副较高', '证据等级': '2A', 'CT': '疗效较好，毒副较高', 'TT': '疗效较差，毒副较低'}, '来曲唑、阿那曲唑\\tTNFSF11\\trs7984870': {'CC': '毒副较高', '证据等级': 3, 'CG': '毒副较低', 'GG': '毒副较低'}, '来曲唑、阿那曲唑\\tCYP19A1\\trs4646': {'AA': '绝经前疗效较好，绝经后疗效较差', '证据等级': '2B', 'AC': '绝经前疗效较差，绝经后疗效较好', 'CC': '绝经前疗效较差，绝经后疗效较好'}, '依西美坦\\tCYP19A1\\trs7176005': {'CC': '毒副较低', '证据等级': 3, 'CT': '毒副较低', 'TT': '毒副较高'}, '依西美坦\\tESR1\\trs2813543': {'AA': '毒副较低', '证据等级': 3, 'AG': '毒副较高', 'GG': '毒副较高'}}\n"
     ]
    }
   ],
   "source": [
    "print(dic1)#基因型解释字典\n",
    "#print(dic)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 450,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "   序号      登记时间             申请单             快递收入单号      采样时间      收样时间  \\\n",
      "0   1  20190812  肿瘤个体化用药基因检测送检单    SF1002402141027  20190807  20190809   \n",
      "1   2  20190812  肿瘤个体化用药基因检测送检单  顺丰SF1002442506350  20190808  20190811   \n",
      "\n",
      "       实验室编号   姓名 性别  年龄  ... rs67376798  rs151264360  rs1042858 rs9937  \\\n",
      "0  17B010560  蔡月桂  女  61  ...         TT        (-/-)         AA     AG   \n",
      "1  17B010563  宋士云  女  67  ...         TT        (-/-)         AA     AG   \n",
      "\n",
      "  rs11598702 rs3892097 rs7984870  rs4646 rs7176005 rs2813543  \n",
      "0         CC        CC        CC      AC        CC        GG  \n",
      "1         TT        CC        GG      CC        CT        GG  \n",
      "\n",
      "[2 rows x 38 columns]\n"
     ]
    }
   ],
   "source": [
    "df_client = pd.read_excel('乳腺癌检测报告.xlsx')\n",
    "print(df_client)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 451,
   "metadata": {},
   "outputs": [],
   "source": [
    "list1 = ['rs8133052', 'rs1801133', 'rs67376798', 'rs1042858', 'rs11598702', 'rs7984870']\n",
    "list2 = ['rs11615']\n",
    "\n",
    "list3 = []"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 452,
   "metadata": {},
   "outputs": [],
   "source": [
    "def modify_result(df_name, list1, list2, list3):\n",
    "    #list1:基因型与数据库相反的位点列表，list2:基因型与数据库反向互补的位点列表 \n",
    "    #list3:基因型与数据库互补的位点列表\n",
    "    reverse_complement = lambda gt: gt.replace('A','t').replace('T','a').replace('G','c').replace('C','g').upper()[::-1]\n",
    "    complement = lambda gt: gt.replace('A','t').replace('T','a').replace('G','c').replace('C','g').upper()\n",
    "    for i in range(df_name.shape[0]):\n",
    "        for line1 in list1:\n",
    "            df_name.at[i, line1] = df_client.at[i, line1][::-1]#将检测结果中与数据库相反的基因型校正\n",
    "        for line2 in list2:\n",
    "            df_name.at[i, line2] = reverse_complement(df_name.at[i, line2])\n",
    "        for line3 in list3:\n",
    "            df_name.at[i, line3] = complement(df_name.at[i, line3])\n",
    "        \n",
    "            \n",
    "        \n",
    "        \n",
    "        \n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 453,
   "metadata": {},
   "outputs": [],
   "source": [
    "modify_result(df_client, list1, list2, list3)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 454,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "   序号      登记时间             申请单             快递收入单号      采样时间      收样时间  \\\n",
      "0   1  20190812  肿瘤个体化用药基因检测送检单    SF1002402141027  20190807  20190809   \n",
      "1   2  20190812  肿瘤个体化用药基因检测送检单  顺丰SF1002442506350  20190808  20190811   \n",
      "\n",
      "       实验室编号   姓名 性别  年龄  ... rs67376798  rs151264360  rs1042858 rs9937  \\\n",
      "0  17B010560  蔡月桂  女  61  ...         TT        (-/-)         AA     AG   \n",
      "1  17B010563  宋士云  女  67  ...         TT        (-/-)         AA     AG   \n",
      "\n",
      "  rs11598702 rs3892097 rs7984870  rs4646 rs7176005 rs2813543  \n",
      "0         CC        CC        CC      AC        CC        GG  \n",
      "1         TT        CC        GG      CC        CT        GG  \n",
      "\n",
      "[2 rows x 38 columns]\n"
     ]
    }
   ],
   "source": [
    "print(df_client)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 455,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "AG\n",
      "0    蔡月桂\n",
      "1    宋士云\n",
      "Name: 姓名, dtype: object\n"
     ]
    }
   ],
   "source": [
    "print(df_client[ 'rs8133052'][0])\n",
    "print(df_client['姓名'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 456,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'蔡月桂': {}, '宋士云': {}}\n"
     ]
    }
   ],
   "source": [
    "list_rs = re.findall(r'rs\\d+', str(df_client.columns))\n",
    "new_df = df_client[list_rs]\n",
    "dic_client = {}\n",
    "for i in range(df_client.shape[0]):\n",
    "    dic_client.setdefault (df_client['姓名'][i], {})\n",
    "print(dic_client)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 457,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'蔡月桂': {'rs1695': 'AG', 'rs8133052': 'AG', 'rs4880': 'AG', 'rs9561778': 'GG', 'rs1045642': 'AA', 'rs13181': 'TT', 'rs699947': 'CC', 'rs11615': 'GG', 'rs1801133': 'AA', 'rs3918290': 'CC', 'rs67376798': 'TT', 'rs151264360': '(-/-)', 'rs1042858': 'AA', 'rs9937': 'AG', 'rs11598702': 'CC', 'rs3892097': 'CC', 'rs7984870': 'CC', 'rs4646': 'AC', 'rs7176005': 'CC', 'rs2813543': 'GG'}, '宋士云': {'rs1695': 'AG', 'rs8133052': 'AG', 'rs4880': 'AG', 'rs9561778': 'GG', 'rs1045642': 'AA', 'rs13181': 'TT', 'rs699947': 'CC', 'rs11615': 'GG', 'rs1801133': 'AA', 'rs3918290': 'CC', 'rs67376798': 'TT', 'rs151264360': '(-/-)', 'rs1042858': 'AA', 'rs9937': 'AG', 'rs11598702': 'CC', 'rs3892097': 'CC', 'rs7984870': 'CC', 'rs4646': 'AC', 'rs7176005': 'CC', 'rs2813543': 'GG'}}\n"
     ]
    }
   ],
   "source": [
    "list_rs = re.findall(r'rs\\d+', str(df_client.columns))\n",
    "for i in range(df_client.shape[0]):\n",
    "    for j in list_rs:\n",
    "        dic_client[df_client['姓名'][i]][j] = df_client[j][0]\n",
    "\n",
    "print(dic_client)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 458,
   "metadata": {},
   "outputs": [],
   "source": [
    "def du_pinggu(string,line_name,zidian):\n",
    "    return zidian[string][dic_client[line_name][string.split('\\t')[2]]]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 462,
   "metadata": {},
   "outputs": [],
   "source": [
    "from collections import OrderedDict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 526,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "疗效较好，毒副较低---2A\n",
      "毒副较低---3\n",
      "毒副较高---3\n",
      "疗效适中，毒副适中---3\n",
      "疗效适中---2B\n",
      "毒副较低---3\n",
      "毒副较低---3\n",
      "疗效较差---3\n",
      "毒副较高---3\n",
      "疗效较差---3\n",
      "疗效较好，毒副较低---2B\n",
      "疗效较好，毒副较高---2A\n",
      "代谢较快，毒副较低---1A\n",
      "毒副较低，代谢较快---1A\n",
      "疗效较好，毒副较高---2A\n",
      "毒副较低---3\n",
      "疗效较好，毒副较低---3\n",
      "代谢较快---2B\n",
      "疗效较差，毒副较高---2A\n",
      "疗效较好，毒副较高---2A\n",
      "毒副较高---3\n",
      "绝经前疗效较差，绝经后疗效较好---2B\n",
      "毒副较低---3\n",
      "毒副较高---3\n"
     ]
    }
   ],
   "source": [
    "list_pinggu = []\n",
    "#dic_pinggu_result = []\n",
    "dic1_keys = [i for i in dic1.keys()]\n",
    "#for i in dic1_keys:\n",
    "#    list_pinggu.append(du_pinggu(i, '蔡月桂', dic1))\n",
    "for i in dic1.keys():\n",
    "    print(dic1[i][dic_client['宋士云'][i.split('\\t')[2]]] + '---' + str(dic1[i]['证据等级']) )\n",
    "    #list_pinggu.append(dic1[i][dic_client['宋士云'][i.split('\\t')[2]]] + '---' + str(dic1[i]['证据等级']))\n",
    "    list_pinggu.append(dic1[i][dic_client['宋士云'][i.split('\\t')[2]]] )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 527,
   "metadata": {},
   "outputs": [],
   "source": [
    "dic_pinggu_result = OrderedDict(zip(dic1_keys, list_pinggu))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 528,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "OrderedDict([('环磷酰胺+表柔比星\\tGSTP1\\trs1695', '疗效较好，毒副较低'), ('环磷酰胺+多柔比星+氟尿嘧啶\\tABCC4\\trs9561778', '毒副较低'), ('环磷酰胺+多柔比星+氟尿嘧啶\\tERCC1\\trs11615', '毒副较高'), ('多柔比星\\tCBR3\\trs8133052', '疗效适中，毒副适中'), ('环磷酰胺\\tSOD2\\trs4880', '疗效适中'), ('环磷酰胺\\tABCC4\\trs9561778', '毒副较低'), ('紫杉醇\\tSOD2\\trs4880', '毒副较低'), ('紫杉醇\\tABCB1\\trs1045642', '疗效较差'), ('多西他赛\\tERCC2\\trs13181', '毒副较高'), ('多西他赛\\tVEGFA\\trs699947', '疗效较差'), ('顺铂、卡铂\\tERCC1\\trs11615', '疗效较好，毒副较低'), ('顺铂、卡铂\\tMTHFR\\trs1801133', '疗效较好，毒副较高'), ('卡培他滨、氟尿嘧啶\\tDPYD\\trs3918290', '代谢较快，毒副较低'), ('卡培他滨、氟尿嘧啶\\tDPYD\\trs67376798', '毒副较低，代谢较快'), ('卡培他滨、氟尿嘧啶\\tTYMS\\trs151264360', '疗效较好，毒副较高'), ('吉西他滨\\tRRM1\\trs1042858', '毒副较低'), ('吉西他滨\\tRRM1\\trs9937', '疗效较好，毒副较低'), ('吉西他滨\\tNT5C2\\trs11598702', '代谢较快'), ('甲氨蝶呤\\tMTHFR\\trs1801133', '疗效较差，毒副较高'), ('他莫昔芬\\tCYP2D6\\trs3892097', '疗效较好，毒副较高'), ('来曲唑、阿那曲唑\\tTNFSF11\\trs7984870', '毒副较高'), ('来曲唑、阿那曲唑\\tCYP19A1\\trs4646', '绝经前疗效较差，绝经后疗效较好'), ('依西美坦\\tCYP19A1\\trs7176005', '毒副较低'), ('依西美坦\\tESR1\\trs2813543', '毒副较高')])\n"
     ]
    }
   ],
   "source": [
    "print(dic_pinggu_result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 529,
   "metadata": {},
   "outputs": [],
   "source": [
    "d_test = {}\n",
    "for i in dic_pinggu_result.keys():\n",
    "    d_test.setdefault(i.split('\\t')[0],[])\n",
    "for i in dic_pinggu_result.keys():\n",
    "    d_test[i.split('\\t')[0]].append(dic_pinggu_result[i])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 583,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'环磷酰胺+表柔比星': ['疗效较好，毒副较低'], '环磷酰胺+多柔比星+氟尿嘧啶': ['毒副较低', '毒副较高'], '多柔比星': ['疗效适中，毒副适中'], '环磷酰胺': ['疗效适中', '毒副较低'], '紫杉醇': ['毒副较低', '疗效较差'], '多西他赛': ['毒副较高', '疗效较差'], '顺铂、卡铂': ['疗效较好，毒副较低', '疗效较好，毒副较高'], '卡培他滨、氟尿嘧啶': ['代谢较快，毒副较低', '毒副较低，代谢较快', '疗效较好，毒副较高'], '吉西他滨': ['毒副较低', '疗效较好，毒副较低', '代谢较快'], '甲氨蝶呤': ['疗效较差，毒副较高'], '他莫昔芬': ['疗效较好，毒副较高'], '来曲唑、阿那曲唑': ['毒副较高', '绝经前疗效较差，绝经后疗效较好'], '依西美坦': ['毒副较低', '毒副较高']}\n"
     ]
    }
   ],
   "source": [
    "print(d_test)#各药物疗效列表的字典"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 607,
   "metadata": {},
   "outputs": [],
   "source": [
    "d_result = {}#临床提示映射\n",
    "#dic_effect = {'毒副':('较低', '适中', '较高'), '代谢':('较慢', '适中', '较快'), '疗效':('较差', '适中', '较好')}\n",
    "#list_effect = []\n",
    "for i, a in d_test.items():\n",
    "    \n",
    "    if len(a) == 1:\n",
    "        d_result[i] = a[0]\n",
    "       \n",
    "    if len(a) > 1:\n",
    "        if i == '来曲唑、阿那曲唑':\n",
    "            d_result[i] = '，'.join(a)\n",
    "        else:\n",
    "        \n",
    "        \n",
    "            list_effect = []\n",
    "            dic_effect = {'毒副':('较低', '适中', '较高'), '代谢':('较慢', '适中', '较快'), '疗效':('较差', '适中', '较好')}\n",
    "            du = re.findall(r'毒副\\w+', str(a))\n",
    "            dai = re.findall(r'代谢\\w+', str(a))\n",
    "            liao = re.findall(r'疗效\\w+', str(a))\n",
    "            for j in [du, dai, liao]:\n",
    "                if len(j) > 1:\n",
    "                    for line in dic_effect.keys():\n",
    "                        if j[0][:2] == line:\n",
    "                \n",
    "                            if len(re.findall(re.escape(dic_effect[line][0]), str(a))) and len(re.findall(re.escape(dic_effect[line][2]), str(a))) or len(re.findall(re.escape(dic_effect[line][0]), str(a))) and len(re.findall(re.escape(dic_effect[line][1]), str(a))):\n",
    "                                list_effect.append(line + dic_effect[line][1])\n",
    "                            if len(re.findall(re.escape(dic_effect[line][1]), str(a))) and len(re.findall(re.escape(dic_effect[line][2]), str(a))) and len(re.findall(re.escape(dic_effect[line][0]), str(a))) == 0:\n",
    "                                list_effect.append(line + dic_effect[line][2])\n",
    "                            if len(re.findall(re.escape(dic_effect[line][0]), str(a))) and len(re.findall(re.escape(dic_effect[line][2]), str(a))) == 0 and len(re.findall(re.escape(dic_effect[line][1]), str(a))) == 0:\n",
    "                                list_effect.append(line + dic_effect[line][0])\n",
    "                            if len(re.findall(re.escape(dic_effect[line][0]), str(a))) and len(re.findall(re.escape(dic_effect[line][2]), str(a))) and len(re.findall(re.escape(dic_effect[line][1]), str(a))):\n",
    "                                list_effect.append(line + dic_effect[line][1])\n",
    "                            if len(re.findall(re.escape(dic_effect[line][2]), str(a))) and len(re.findall(re.escape(dic_effect[line][1]), str(a))) == 0 and len(re.findall(re.escape(dic_effect[line][0]), str(a))) == 0:\n",
    "                                list_effect.append(line + dic_effect[line][2])\n",
    "                if len(j) == 1:\n",
    "                    list_effect.append(j[0])\n",
    "                else:\n",
    "                    pass\n",
    "            d_result[i] = '，'.join(list_effect)\n",
    "        \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 608,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'环磷酰胺+表柔比星': '疗效较好，毒副较低', '环磷酰胺+多柔比星+氟尿嘧啶': '毒副适中', '多柔比星': '疗效适中，毒副适中', '环磷酰胺': '毒副较低，疗效适中', '紫杉醇': '毒副较低，疗效较差', '多西他赛': '毒副较高，疗效较差', '顺铂、卡铂': '毒副适中，疗效较好', '卡培他滨、氟尿嘧啶': '毒副适中，代谢较快，疗效较好', '吉西他滨': '毒副较低，代谢较快，疗效较好', '甲氨蝶呤': '疗效较差，毒副较高', '他莫昔芬': '疗效较好，毒副较高', '来曲唑、阿那曲唑': '毒副较高，绝经前疗效较差，绝经后疗效较好', '依西美坦': '毒副适中'}\n"
     ]
    }
   ],
   "source": [
    "print(d_result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 601,
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "du = []\n",
    "dai = []\n",
    "liao = []\n",
    "a =  ['毒副较高', '绝经前疗效较差，绝经后疗效较好']\n",
    "#a = ['疗效较好，毒副较低---2A']\n",
    "#for i in ['代谢', '疗效', '毒副']: \n",
    "#    if str(a).count(i) == 1:\n",
    "#        rex = re.escape(i)+r'\\w+'\n",
    "#        du.append(re.findall(rex, str(a))[0])\n",
    "#    if str(a).count(i) > 1:\n",
    "#        multi_rex = re.escape(i)+r'\\w+'\n",
    "#        dai = (re.findall(multi_rex, str(a)))\n",
    "        \n",
    "        \n",
    "du = re.findall(r'毒副\\w+', str(a))\n",
    "dai = re.findall(r'代谢\\w+', str(a))\n",
    "liao = re.findall(r'疗效\\w+', str(a))\n",
    "list_effect = []\n",
    "#print(du)\n",
    "#print(dai)\n",
    "#print(liao)\n",
    "dic_effect = {'毒副':('较低', '适中', '较高'), '代谢':('较慢', '适中', '较快'), '疗效':('较差', '适中', '较好')}\n",
    "\n",
    "for j in [du, dai, liao]:\n",
    "    if len(j) > 1:\n",
    "        for line in dic_effect.keys():\n",
    "            if j[0][:2] == line:\n",
    "                \n",
    "                if len(re.findall(re.escape(dic_effect[line][0]), str(a))) and len(re.findall(re.escape(dic_effect[line][2]), str(a))) or len(re.findall(re.escape(dic_effect[line][0]), str(a))) and len(re.findall(re.escape(dic_effect[line][1]), str(a))):\n",
    "                    list_effect.append(line + dic_effect[line][1])\n",
    "                if len(re.findall(re.escape(dic_effect[line][1]), str(a))) and len(re.findall(re.escape(dic_effect[line][2]), str(a))) and len(re.findall(re.escape(dic_effect[line][0]), str(a))) == 0:\n",
    "                    list_effect.append(line + dic_effect[line][2])\n",
    "                if len(re.findall(re.escape(dic_effect[line][0]), str(a))) and len(re.findall(re.escape(dic_effect[line][2]), str(a))) == 0 and len(re.findall(re.escape(dic_effect[line][1]), str(a))) == 0:\n",
    "                    list_effect.append(line + dic_effect[line][0])\n",
    "                if len(re.findall(re.escape(dic_effect[line][0]), str(a))) and len(re.findall(re.escape(dic_effect[line][2]), str(a))) and len(re.findall(re.escape(dic_effect[line][1]), str(a))):\n",
    "                    list_effect.append(line + dic_effect[line][1])\n",
    "                if len(re.findall(re.escape(dic_effect[line][2]), str(a))) and len(re.findall(re.escape(dic_effect[line][1]), str(a))) == 0 and len(re.findall(re.escape(dic_effect[line][0]), str(a))) == 0:\n",
    "                    list_effect.append(line + dic_effect[line][2])\n",
    "    if len(j) == 1:\n",
    "        list_effect.append(j[0])\n",
    "    else:\n",
    "        pass\n",
    "\n",
    "               \n",
    "                \n",
    "                \n",
    "                \n",
    "            \n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 609,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "   序号      登记时间             申请单             快递收入单号      采样时间      收样时间  \\\n",
      "0   1  20190812  肿瘤个体化用药基因检测送检单    SF1002402141027  20190807  20190809   \n",
      "1   2  20190812  肿瘤个体化用药基因检测送检单  顺丰SF1002442506350  20190808  20190811   \n",
      "\n",
      "       实验室编号   姓名 性别  年龄  ... rs67376798  rs151264360  rs1042858 rs9937  \\\n",
      "0  17B010560  蔡月桂  女  61  ...         TT        (-/-)         AA     AG   \n",
      "1  17B010563  宋士云  女  67  ...         TT        (-/-)         AA     AG   \n",
      "\n",
      "  rs11598702 rs3892097 rs7984870  rs4646 rs7176005 rs2813543  \n",
      "0         CC        CC        CC      AC        CC        GG  \n",
      "1         TT        CC        GG      CC        CT        GG  \n",
      "\n",
      "[2 rows x 38 columns]\n"
     ]
    }
   ],
   "source": [
    "print(df_client)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 630,
   "metadata": {},
   "outputs": [],
   "source": [
    "dic_info_client = {}\n",
    "for i in range(df_client.shape[0]):\n",
    "    dic_info_client.setdefault(df_client['姓名'][i], {})\n",
    "    dic_info_client[df_client['姓名'][i]]['采样日期'] = str(df_client['采样时间'][i])[:4] + '-' + str(df_client['采样时间'][i])[4:6] + '-' + str(df_client['采样时间'][i])[6:8]\n",
    "    dic_info_client[df_client['姓名'][i]]['收样日期'] = str(df_client['收样时间'][i])[:4] + '-' + str(df_client['收样时间'][i])[4:6] + '-' + str(df_client['收样时间'][i])[6:8]\n",
    "    dic_info_client[df_client['姓名'][i]]['姓名'] = df_client['姓名'][i]\n",
    "    dic_info_client[df_client['姓名'][i]]['性别'] = df_client['性别'][i]\n",
    "    dic_info_client[df_client['姓名'][i]]['年龄'] = df_client['年龄'][i]\n",
    "    dic_info_client[df_client['姓名'][i]]['样本编号'] = df_client['实验室编号'][i]\n",
    "    dt = datetime.date.today()\n",
    "    reportdate = '{}-{}-{}'.format(str(dt.year), str(dt.month), str(dt.day))\n",
    "    dic_info_client[df_client['姓名'][i]]['报告日期'] = reportdate\n",
    "        "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 631,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'蔡月桂': {'采样日期': '2019-08-07', '收样日期': '2019-08-09', '姓名': '蔡月桂', '性别': '女', '年龄': 61, '样本编号': '17B010560', '报告日期': '2019-8-20'}, '宋士云': {'采样日期': '2019-08-08', '收样日期': '2019-08-11', '姓名': '宋士云', '性别': '女', '年龄': 67, '样本编号': '17B010563', '报告日期': '2019-8-20'}}\n"
     ]
    }
   ],
   "source": [
    "print(dic_info_client)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
